



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/435, C12N 1/13, 5/10, 15/12, 15/63, A61K 38/17	A1	(11) International Publication Number: WO 99/15556 (43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: PCT/US98/20675 (22) International Filing Date: 28 September 1998 (28.09.98) (30) Priority Data: 08/938,365 26 September 1997 (26.09.97) US (71) Applicant: MILLENNIUM BIOTHERAPEUTICS, INC. [US/US]; 620 Memorial Drive, Cambridge, MA 02142 (US). (72) Inventor: PAN, Yang; 6 Hamilton Road #1, Brookline, MA 02146 (US). (74) Agent: MEIKLEJOHN, Anita, L.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HUCHORDIN AND USES THEREOF (57) Abstract The invention relates to huchordin polypeptides, nucleic acid molecules encoding huchordin, and uses thereof.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

HUCHORDIN AND USES THEREOF

Summary of the Invention

The invention relates to the discovery and characterization of a new human gene, *huchordin*, and
5 *huchordin* polypeptides. Northern blot analysis of
huchordin mRNA reveals that the *huchordin* gene is
expressed as an approximately 7.5 kb transcript in adult
and fetal liver and as an approximately 4.4 kb transcript
in adult brain, heart, and pancreas. An additional
10 approximately 2.7 kb transcript is observed in fetal
liver.

A cDNA corresponding to *huchordin* has been cloned
(SEQ ID NO:1). Nucleotides 1 to 2601 (SEQ ID NO:3) of
this cDNA encode an 867 amino acid protein (SEQ ID NO:2)
15 that has homology to *Xenopus* chordin (Sasai et al., Cell
79:779, 1994).

The invention encompasses nucleic acids that have a
sequence that is substantially identical to a *huchordin*
nucleic acid sequence. A nucleic acid which is
20 substantially identical to a given reference nucleic acid
molecule is hereby defined as a nucleic acid having a
sequence that has at least 85%, preferably 90%, and more
preferably 95%, 98%, 99% or more identity to the sequence
of the given reference nucleic acid molecule, e.g., the
25 nucleic acid sequence of SEQ ID NO:1.

A polypeptide or nucleic acid molecule which is
"substantially identical" to a given reference
polypeptide or nucleic acid molecule is a polypeptide or
nucleic acid molecule having a sequence that has at least
30 85%, preferably 90%, and more preferably 95%, 98%, 99% or
more identity to the sequence of the given reference
polypeptide sequence or nucleic acid molecule, e.g., the
polypeptide sequence of SEQ ID NO:2 or the nucleic acid
sequence of SEQ ID NO:1.

-2-

The nucleic acid molecules of the invention can be inserted into vectors, described below, which will facilitate expression of the gene. The nucleic acid molecules and polypeptides of the invention can be used
5 directly as diagnostic or therapeutic agents, or (in the case of a polypeptide) can be used to generate antibodies that, in turn, are therapeutically useful. Accordingly, expression vectors containing the nucleic acid molecules of the invention, cells transfected with these vectors,
10 the polypeptides expressed by these vectors, and antibodies generated against either the entire polypeptide or an antigenic fragment thereof are among the preferred embodiments.

A transformed cell is any cell into which (or into
15 an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid molecule encoding a polypeptide of the invention (e.g., a huchordin polypeptide).

An isolated nucleic acid molecule is a nucleic acid
20 molecule that is separated from the 5' and 3' coding sequences with which it is immediately contiguous in the naturally occurring genome of an organism. Isolated nucleic acid molecules include nucleic acid molecule which are not naturally occurring, e.g., nucleic acid
25 molecules created by recombinant DNA techniques.

Nucleic acid molecules include both RNA and DNA, including cDNA, genomic DNA, and synthetic (e.g., chemically synthesized) DNA. Where single-stranded, the nucleic acid molecule may be a sense strand or an
30 antisense strand.

The invention also encompasses nucleic acid molecules that hybridize, preferably under stringent conditions, to a nucleic acid molecule encoding a huchordin polypeptide (e.g., a nucleic acid molecule
35 having the sequence shown in SEQ ID NO:1, a nucleic acid molecule (SEQ ID NO:3) having the sequence of the

-3-

huchordin encoding portion of the sequence of SEQ ID NO:1), or a nucleic acid molecule having the sequence of the protein coding portion of ATCC deposit No. 98481. Preferably the hybridizing nucleic acid molecule consists
5 of 400, more preferably 200 nucleotides. Preferred hybridizing nucleic acid molecules have a biological activity possessed by huchordin.

The invention also features substantially pure or isolated huchordin polypeptides, including those that
10 correspond to various functional domains of huchordin, or fragments thereof. The polypeptides of the invention encompass amino acid sequences that are substantially identical to the amino acid sequence shown in Fig. 1 (SEQ ID NO:2).

15 The polypeptides of the invention can also be chemically synthesized, or they can be purified from tissues in which they are naturally expressed, according to standard biochemical methods of purification.

Also included in the invention are functional
20 polypeptides which possess one or more of the biological functions or activities of huchordin. These functions include the ability to bind some or all of the proteins which normally bind to huchordin. A functional polypeptide is also considered within the scope of the
25 invention if it serves as an antigen for production of antibodies that specifically bind to huchordin. In many cases, functional polypeptides retain one or more domains present in the naturally-occurring form of the polypeptide.

30 The functional polypeptides may contain a primary amino acid sequence that has been modified from those disclosed herein. Preferably these modifications consist of conservative amino acid substitutions, as described herein.

35 The terms "protein" and "polypeptide" are used herein to describe any chain of amino acids, regardless

-4-

of length or post-translational modification (for example, glycosylation or phosphorylation). Thus, the term "huchordin polypeptides" includes full-length, naturally occurring huchordin protein, as well a
5 recombinantly or synthetically produced polypeptide that corresponds to a full-length, naturally occurring huchordin protein or to particular domains or portions of a naturally occurring protein. The term also encompasses mature huchordin which has an added amino-terminal
10 methionine (useful for expression in prokaryotic cells).

The term "purified" as used herein refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical
15 precursors or other chemicals when chemically synthesized.

Polypeptides or other compounds of interest are said to be "substantially pure" when they are within preparations that are at least 60% by weight (dry weight)
20 the compound of interest. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight the compound of interest. Purity can be measured by any appropriate standard method, for example, by column chromatography,
25 polyacrylamide gel electrophoresis, or HPLC analysis.

Where a particular polypeptide or nucleic acid molecule is said to have a specific percent identity to a reference polypeptide or nucleic acid molecule of a defined length, the percent identity is relative to the
30 reference polypeptide or nucleic acid molecule. Thus, a peptide that is 50% identical to a reference polypeptide that is 100 amino acids long can be a 50 amino acid polypeptide that is completely identical to a 50 amino acid long portion of the reference polypeptide. It might
35 also be a 100 amino acid long polypeptide which is 50% identical to the reference polypeptide over its entire

-5-

length. Of course, many other polypeptides will meet the same criteria. The same rule applies for nucleic acid molecules.

For polypeptides, the length of the reference
5 polypeptide sequence will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids, 50 amino acids, or 100 amino acids. For
10 nucleic acids, the length of the reference nucleic acid sequence will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 100 nucleotides or 300 nucleotides.

In the case of polypeptide sequences which are less
15 than 100% identical to a reference sequence, the non-identical positions are preferably, but not necessarily, conservative substitutions for the reference sequence. Conservative substitutions typically include
20 substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine and glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.

Sequence identity can be measured using sequence
25 analysis software (for example, the Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705), with the default parameters as specified therein.

30 The invention also features antibodies, e.g., monoclonal, polyclonal, and engineered antibodies, which specifically bind huchordin. By "specifically binds" is meant an antibody that recognizes and binds to a particular antigen, e.g., a huchordin polypeptide of the
35 invention, but which does not substantially recognize or

-6-

bind to other molecules in a sample, e.g., a biological sample, which includes huchordin.

The invention also features antagonists and agonists of huchordin that can inhibit or enhance, respectively, one or more of the biological activities of huchordin. Suitable antagonists can include small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), antibodies that bind and "neutralize" huchordin (as described below), polypeptides which compete with a native form of huchordin for binding to a protein, e.g., a member of the TGF- β superfamily, and nucleic acid molecules that interfere with transcription of huchordin (for example, antisense nucleic acid molecules and ribozymes). Agonists of huchordin also include small and large molecules, and antibodies other than neutralizing antibodies.

The invention also features molecules which can increase or decrease the expression of huchordin (e.g., by influencing transcription or translation). Small molecules (i.e., molecules with a molecular weight below about 500), large molecules (i.e., molecules with a molecular weight above about 500), and nucleic acid molecules that can be used to inhibit the expression of huchordin (for example, antisense and ribozyme molecules) or to enhance the expression of huchordin (for example, molecules that bind to a huchordin transcription regulatory sequence and increase huchordin transcription).

The invention also features molecules which alter the cellular localization of huchordin. Such molecules can be used to treat disorders associated with aberrant cellular localization of huchordin.

In addition, the invention features substantially pure polypeptides that functionally interact with

-7-

huchordin, e.g., novel members of the TGF- β superfamily, and the nucleic acid molecules that encode them.

The invention encompasses methods for treating disorders associated with aberrant expression, activity
5 or localization of huchordin. Thus, the invention includes methods for treating disorders associated with excessive expression or activity of huchordin. Such methods entail administering a compound which decreases the expression or activity of huchordin. The invention
10 also includes methods for treating disorders associated with insufficient expression or activity of huchordin. These methods entail administering a compound which increases the expression or activity of huchordin.

The invention also features methods for detecting a
15 huchordin polypeptide. Such methods include: obtaining a biological sample; contacting the sample with an antibody that specifically binds huchordin under conditions which permit specific binding; and detecting any antibody-huchordin complexes formed.

20 In addition, the present invention encompasses methods and compositions for the diagnostic evaluation, typing, and prognosis of disorders associated with inappropriate expression or activity of huchordin. For example, the nucleic acid molecules of the invention can
25 be used as diagnostic hybridization probes to detect, for example, inappropriate expression of huchordin or mutations in the huchordin gene. Such methods may be used to classify cells by the level of huchordin expression.

30 Thus, the invention features a method for diagnosing a disorder associated with aberrant activity of huchordin, the method including obtaining a biological sample from a patient and measuring huchordin activity in the biological sample, wherein increased or decreased
35 huchordin activity in the biological sample compared to a

-8-

control indicates that the patient suffers from a disorder associated with aberrant activity of huchordin.

The present invention further provides for diagnostic kits for the practice of such methods.

5 The invention features methods of identifying compounds that modulate the expression or activity of huchordin by assessing the expression or activity of huchordin in the presence and absence of a selected compound. A difference in the level of expression or
10 activity of huchordin in the presence and absence of the selected compound indicates that the selected compound is capable of modulating expression or activity or huchordin. Expression can be assessed either at the level of gene expression (e.g., by measuring mRNA) or
15 protein expression by techniques that are well known to skilled artisans. The activity of huchordin can be assessed functionally.

Also included in the invention are: a method for detecting huchordin in a sample, the method including:

- 20 (a) obtaining a biological sample;
 (b) contacting the biological sample with an antibody that specifically binds huchordin under conditions that allow the formation of huchordin-antibody complexes; and
25 (c) detecting the complexes, if any, as an indication of the presence of huchordin in the sample.

In another aspect, the invention features a method of identifying a compound that modulates the activity of huchordin, the method including comparing the level of
30 activity of huchordin in a cell in the presence and absence of a selected compound, wherein a difference in the level of activity in the presence and absence of the selected compound indicates that the selected compound modulates the activity of huchordin.

35 The invention also features a method for diagnosing a disorder associated with aberrant expression of

-9-

huchordin, the method including obtaining a biological sample from a patient and measuring huchordin expression in the biological sample, wherein increased or decreased huchordin expression in the biological sample compared to
5 a control indicates that the patient suffers from a disorder associated with aberrant expression of huchordin.

In another aspect the invention features a method for diagnosing a disorder associated with aberrant
10 activity of huchordin, the method including obtaining a biological sample from a patient and measuring huchordin activity in the biological sample, wherein increased or decreased huchordin activity in the biological sample compared to a control indicates that the patient suffers
15 from a disorder associated with aberrant activity of huchordin.

The preferred methods and materials are described below in examples which are meant to illustrate, not limit, the invention. Skilled artisans will recognize
20 methods and materials that are similar or equivalent to those described herein, and that can be used in the practice or testing of the present invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as
25 commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are
30 described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials,
35 methods, and examples are illustrative only and are not intended to be limiting.

-10-

Other features and advantages of the invention will be apparent from the detailed description, and from the claims.

Brief Description of the Drawing

5 Figure 1 is a depiction of the sequence of a cDNA encoding huchordin (SEQ ID NO:1) and the deduced amino sequence (SEQ ID NO:2) of huchordin.

Figure 2 is an alignment of a portion of the amino acid sequence of huchordin (upper sequence of each pair) and a portion of amino acid sequence of *Xenopus* chordin (lower sequence of each pair; SEQ ID NO:4).

Detailed Description

Huchordin, a human protein described here for the first time, is a 867 amino acid protein that is predicted to be a secreted protein. A putative signal sequence encompasses amino acids 1-26 of huchordin.

Huchordin bears homology to *Xenopus* chordin (Sasai et al., *Cell* 79:779, 1994). Like *Xenopus* chordin, huchordin includes several cysteine-rich repeats. *Xenopus* chordin includes four such repeats (R1, R2, R3, and R4) of 58-74 residues (Sasai et al., *Cell* 79:779, 1994) each of which includes 10 cysteine residues at conserved positions.

Huchordin contains three intact cysteine-rich repeats (amino acids 51-125; amino acids 696-762; and amino acids 784-844), corresponding to R1, R3, and R4 of chordin. The huchordin cysteine-rich repeat (amino acids 644-674) corresponding to R2 of chordin contains only six of the 10 conserved cys residues and is properly considered a half repeat.

Four potential N-glycosylation sites (217, 351, 365, and 434) are located between R1 and R2 in huchordin. Chordin also has four such sites. Two of the potential

-11-

huchordin N-glycosylation sites N351 at N434 are in positions that are conserved in chordin.

Overall, the *huchordin* gene described herein has 66% homology at the nucleotide level to the *Xenopus chordin* gene, and the *huchordin* protein described herein has 53% homology to *Xenopus chordin* protein at the amino acid level.

Huchordin Nucleic Acid Molecules

The *huchordin* nucleic acid molecules of the invention can be cDNA, genomic DNA, synthetic DNA, or RNA, and can be double-stranded or single-stranded (i.e., either a sense or an antisense strand). Fragments of these molecules are also considered within the scope of the invention, and can be produced, for example, by the polymerase chain reaction (PCR) or generated by treatment with one or more restriction endonucleases. A ribonucleic acid (RNA) molecule encoding *huchordin* can be produced by *in vitro* transcription.

The nucleic acid molecules of the invention can contain naturally occurring sequences, or sequences that differ from those that occur naturally, but, due to the degeneracy of the genetic code, encode the same polypeptide (for example, the polypeptide of SEQ ID NO:2). In addition, these nucleic acid molecules are not limited to sequences that only encode polypeptides, and thus, can include some or all of the non-coding sequences that lie upstream or downstream from the *huchordin* coding sequence.

The nucleic acid molecules of the invention can be synthesized (for example, by phosphoramidite-based synthesis) or obtained from a biological cell (e.g., by cDNA cloning), such as the cell of a mammal. Thus, the nucleic acids can be those of a human, mouse, rat, guinea pig, cow, sheep, horse, pig, rabbit, monkey, dog, or cat.

-12-

Combinations or modifications of the nucleotides within these types of nucleic acids are also encompassed.

In addition, the isolated nucleic acid molecules of the invention encompass fragments that are not found as
5 such in the natural state. Thus, the invention encompasses recombinant molecules, such as those in which a nucleic acid molecule (for example, an isolated nucleic acid molecule encoding huchordin) is incorporated into a vector (for example, a plasmid or viral vector) or into
10 the genome of a heterologous cell (or the genome of a homologous cell, at a position other than the natural chromosomal location). Recombinant nucleic acid molecules and uses therefor are discussed further below.

The invention encompasses peptide nucleic acids
15 (PNA) and PNA-DNA chimeras having the sequence of a portion of the *huchordin* gene. DNA oligomers and PNA-DNA chimeric oligomers can be used for antisense inhibition (i.e., inhibition of translation) and anti-gene inhibition (i.e., inhibition of transcription) (Hyrup et
20 al., *Bioorganic & Medicinal Chem.* 4:5, 1996; Finn et al., *Nucl. Acids Res.* 24: 33357, 1996). PNA oligomer can also be used in DNA pre-gel hybridization as an alternative to Southern hybridization.

In the event the nucleic acid molecules of the
25 invention encode or act as antisense molecules, they can be used for example, to regulate translation of huchordin mRNA. Techniques associated with the use of huchordin nucleic acid molecules for detection or regulation of
huchordin expression can be used to diagnose and/or treat
30 disorders associated with aberrant huchordin expression. These nucleic acid molecules are discussed further below in the context of their clinical utility.

The invention encompasses single-stranded nucleic acid probes which hybridize to a huchordin nucleic acid
35 molecule (e.g., the nucleic acid molecule of SEQ ID NO:1). Such probes can be used diagnostic methods to

-13-

detect mutations in the huchordin gene. For example, probes can be used to create a high density oligonucleotide probe array which can be used diagnostically to detect mutations and allelic variations
5 in the *huchordin* gene (Cronin et al., *Human Mutation* 7:244, 1996).

Also within the invention are single-stranded nucleic acid primers which can be used to PCR amplify all or part of a huchordin-encoding nucleic acid molecule.

10 The invention also encompasses nucleic acid molecules that hybridize under stringent conditions to a nucleic acid molecule encoding a huchordin polypeptide. The protein encoding portion of the cDNA sequence described herein (SEQ ID NO:1) can be used to identify
15 these nucleic acid molecules, which include, for example, nucleic acids that encode homologous polypeptides in other mammalian species, splice variants of the huchordin gene in humans or other mammals, and allelic variants of the *huchordin* gene or the genes encoding homologs of
20 huchordin in other mammals (a naturally-occurring mammalian gene). Further, genes may exist at other genetic loci within the genome that encode proteins which have extensive homology to huchordin polypeptides or one or more domains of huchordin polypeptides. Accordingly,
25 the invention features methods of detecting and isolating these nucleic acid molecules. Using these methods, a sample (for example, a nucleic acid library, such as a cDNA or genomic library) is contacted (or "screened") with a huchordin-specific probe (for example, a fragment
30 of SEQ ID NO:1 that is at least 25 or 50 nucleotides long). The probe will selectively hybridize to nucleic acids encoding related polypeptides (or to complementary sequences thereof). The term "selectively hybridize" is used to refer to an event in which a probe binds to
35 nucleic acids encoding huchordin (or to complementary sequences thereof) to a detectably greater extent than to

-14-

nucleic acids encoding *Xenopus* chordin. The probe, which can contain at least 25 (for example, 25, 50, 100, or 200 nucleotides) can be produced using any of several standard methods (see, for example, Ausubel et al., "Current Protocols in Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & Sons, Inc., NY, 1989). For example, the probe can be generated using PCR amplification methods in which oligonucleotide primers are used to amplify a huchordin-specific nucleic acid sequence that can be used as a probe to screen a nucleic acid library and thereby detect nucleic acid molecules (within the library) that hybridize to the probe.

One single-stranded nucleic acid is said to hybridize to another if a duplex forms between them. This occurs when one nucleic acid contains a sequence that is the reverse and complement of the other (this same arrangement gives rise to the natural interaction between the sense and antisense strands of DNA in the genome and underlies the configuration of the "double helix"). Complete complementarity between the hybridizing regions is not required in order for a duplex to form; it is only necessary that the number of paired bases is sufficient to maintain the duplex under the hybridization conditions used.

Typically, hybridization conditions are of low to moderate stringency. These conditions favor specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly matched sequences to occur as well. After hybridization, the nucleic acids can be "washed" under moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary).

-15-

As is known in the art, the optimal conditions for washing are determined empirically, often by gradually increasing the stringency. The parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the lower the salt concentration and the higher the temperature, the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or lower than that of the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can also be altered. For example, use of a destabilizing agent, such as formamide, alters the stringency conditions.

In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each nucleic acid. The length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine-like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization. An additional consideration is whether one of the nucleic acids is immobilized (for example, on a filter).

An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate;

-16-

2X SSC is 10-fold more concentrated than 0.2X SSC). Nucleic acids are hybridized at 42°C in 2X SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2X SSC/0.1% SDS at room temperature (for conditions of low stringency); 0.2X SSC/0.1% SDS at 42°C (for conditions of moderate stringency); and 0.1X SSC at 68°C (for conditions of high stringency). Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above). Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically.

A second set of conditions that are considered "stringent conditions" are those in which hybridization is carried out at 50°C in Church buffer (7% SDS, 0.5% NaHPO₄, 1 M EDTA, 1% BSA) and washing is carried out at 50°C in 2X SSC.

As an alternative to screening a cDNA library, a human total genomic DNA library can be screened using *huchordin* probes. *Huchordin*-positive clones can then be sequenced and, further, the intron/exon structure of the human *huchordin* gene can be elucidated. Once genomic sequence is obtained, oligonucleotide primers can be designed based on the sequence for use in the isolation, via, for example, Reverse Transcriptase-coupled PCR, of *huchordin* splice variants.

Further, a previously unknown gene sequence can be isolated by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences within the *huchordin* cDNAs defined herein. The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express a *huchordin* gene allele. The PCR product can be subcloned and sequenced to insure that the

-17-

amplified sequences represent the sequences of a *huchordin*-like gene nucleic acid sequence.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to screen a genomic library.

PCR technology also can be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid can then be "tailed" with guanines using a standard terminal transferase reaction, the hybrid can be digested with RNAase H, and second strand synthesis can then be primed with a poly-C primer. Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g., Sambrook et al., *supra*; and Ausubel et al., *supra*.

In cases where the gene identified is the normal (wild type) gene, this gene can be used to isolate mutant alleles of the gene. Such an isolation is preferable in processes and disorders which are known or suspected to have a genetic basis.

A cDNA of a mutant gene can be isolated, for example, by using PCR, a technique which is well-known to one skilled in the art. In this case, the first cDNA strand can be synthesized by hybridizing a oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected of being expressed in an individual putatively carrying the mutant allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA can then be synthesized using an oligonucleotide

-18-

that hybridizes specifically to the 5'-end of the normal gene. Using these two primers, the product is then amplified via PCR, cloned into a suitable vector, and subjected to DNA sequence analysis by methods well known in the art. By comparing the DNA sequence of the mutant gene to that of the normal gene, the mutation(s) responsible for the loss or alteration of function of the mutant gene product can be ascertained.

Alternatively, a genomic or cDNA library can be constructed and screened using DNA or RNA, respectively, from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. The normal gene or any suitable fragment thereof can then be labeled and used as a probe to identify the corresponding mutant allele in the library. The clone containing this gene can then be purified through methods routinely practiced in the art, and subjected to sequence analysis using standard techniques as described herein.

Additionally, an expression library can be constructed using DNA isolated from or cDNA synthesized from a tissue known to or suspected of expressing the gene of interest in an individual suspected of or known to carry the mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal gene product, as described herein. For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor.

In cases where the mutation results in an expressed gene product with altered function (e.g., as a result of a missense mutation), a polyclonal set of antibodies is likely to cross-react with the mutant gene product. Library clones detected via their reaction with such

-19-

labeled antibodies can be purified and subjected to sequence analysis as described herein.

Once detected, the nucleic acid molecules can be isolated by any of a number of standard techniques (see, 5 for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual," 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

The invention also encompasses: (a) expression vectors that contain any of the foregoing huchordin- 10 related coding sequences and/or their complements (that is, "antisense" sequence); (b) expression vectors that contain any of the foregoing huchordin-related coding sequences operatively associated with a regulatory element (examples of which are given below) that directs 15 the expression of the coding sequences; (c) expression vectors containing, in addition to sequences encoding a huchordin polypeptide, nucleic acid sequences that are unrelated to nucleic acid sequences encoding huchordin, such as molecules encoding a reporter, a marker, or a 20 portion of an immunoglobulin; and (d) genetically engineered host cells that contain any of the foregoing expression vectors and thereby express the nucleic acid molecules of the invention in the host cell.

Recombinant nucleic acid molecules can contain a 25 sequence encoding a soluble huchordin polypeptide, mature huchordin (e.g., amino acids 27-867 of SEQ ID NO:2), or huchordin having a signal sequence. The full length huchordin polypeptide, a domain of huchordin, or a fragment thereof may be fused to additional polypeptides, 30 as described below. Similarly, the nucleic acid molecules of the invention can encode the mature form of huchordin or a form that encodes a polypeptide which facilitates secretion. In the latter instance, the polypeptide is typically referred to as a proprotein, 35 which can be converted into an active form by removal of the signal sequence, for example, within the host cell.

-20-

The regulatory elements referred to above include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements, which are known to those skilled in the art, and which drive or
5 otherwise regulate gene expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major
10 operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

15 Similarly, the nucleic acid can form part of a hybrid gene encoding additional polypeptide sequences, for example, sequences that function as a marker or reporter. Examples of marker or reporter genes include β -lactamase, chloramphenicol acetyltransferase (CAT),
20 adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo^r, G418^r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT). As
25 with many of the standard procedures associated with the practice of the invention, skilled artisans will be aware of additional useful reagents, for example, of additional sequences that can serve the function of a marker or reporter. Generally, the hybrid polypeptide will include
30 a first portion and a second portion; the first portion being a huchordin polypeptide and the second portion being, for example, the reporter described above or an immunoglobulin constant region.

The expression systems that may be used for purposes
35 of the invention include, but are not limited to, microorganisms such as bacteria (for example, *E. coli* and

-21-

B. subtilis) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing the nucleic acid molecules of the invention; yeast (for example, *Saccharomyces* and *Pichia*) transformed
5 with recombinant yeast expression vectors containing the nucleic acid molecules of the invention (preferably containing the nucleic acid sequence encoding huchordin (contained within SEQ ID NO:Y)); insect cell systems infected with recombinant virus expression vectors (for
10 example, baculovirus) containing the nucleic acid molecules of the invention; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression
15 vectors (for example, Ti plasmid) containing huchordin nucleotide sequences; or mammalian cell systems (for example, COS, CHO, BHK, 293, VERO, HeLa, MDCK, WI38, and NIH 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome
20 of mammalian cells (for example, the metallothionein promoter) or from mammalian viruses (for example, the adenovirus late promoter and the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors
25 may be advantageously selected depending upon the use intended for the gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions containing huchordin polypeptides or for
30 raising antibodies to those polypeptides, vectors that are capable of directing the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther et al.,
35 *EMBO J.* 2:1791, 1983), in which the coding sequence of the insert may be ligated individually into the vector in

-22-

frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye and Inouye, *Nucleic Acids Res.* 13:3101-3109, 1985; Van Heeke and Schuster, *J. Biol. Chem.* 264:5503-5509, 1989); and the
5 like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by
10 elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, *Autographa californica* nuclear
15 polyhydrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The coding sequence of the insert may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed
20 under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by
25 the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed. (for example, see Smith et al., *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051).

30 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the nucleic acid molecule of the invention may be ligated to an adenovirus transcription/translation control complex, for
35 example, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the

-23-

adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (for example, region E1 or E3) will result in a recombinant virus that is viable and capable of
5 expressing a huchordin gene product in infected hosts (for example, see Logan and Shenk, *Proc. Natl. Acad. Sci. USA* 81:3655-3659, 1984).

Specific initiation signals may also be required for efficient translation of inserted nucleic acid molecules.
10 These signals include the ATG initiation codon and adjacent sequences. In cases where an entire gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may
15 be needed. However, in cases where only a portion of the coding sequence is inserted, e.g., only the portion encoding the mature form of a secreted protein, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the
20 initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of
25 expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., *Methods in Enzymol.* 153:516-544, 1987):

In addition, a host cell strain may be chosen which
30 modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (for example, glycosylation) and processing (for example, cleavage) of protein products may be important for the function of the
35 protein. Different host cells have characteristic and specific mechanisms for the post-translational processing

-24-

and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host
5 cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. The mammalian cell types listed above are among those that could serve as suitable host cells.

10 For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the huchordin sequences described above may be engineered. Rather than using expression vectors which contain viral origins of
15 replication, host cells can be transformed with DNA controlled by appropriate expression control elements (for example, promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the
20 foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into
25 their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express huchordin. Such engineered cell lines may be particularly useful in screening and evaluation of
30 compounds that affect the endogenous activity of the gene product.

A number of selection systems can be used. For example, the herpes simplex virus thymidine kinase (Wigler, et al., *Cell* 11:223, 1977), hypoxanthine-guanine
35 phosphoribosyltransferase (Szybalska and Szybalski, *Proc. Natl. Acad. Sci. USA* 48:2026, 1962), and adenine

-25-

phosphoribosyltransferase (Lowy, et al., *Cell* 22:817, 1980) genes can be employed in tk⁻, hgp⁻ or ap⁻ cells, respectively. Also, anti-metabolite resistance can be used as the basis of selection for the following genes:

5 dhfr, which confers resistance to methotrexate (Wigler et al., *Proc. Natl. Acad. Sci. USA* 77:3567, 1980; O'Hare et al., *Proc. Natl. Acad. Sci. USA* 78:1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, *Proc. Natl. Acad. Sci. USA* 78:2072, 1981); neo,

10 which confers resistance to the aminoglycoside G-418 (Colberre-Garapin et al., *J. Mol. Biol.* 150:1, 1981); and hyg^r, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147, 1984).

Huchordin nucleic acid molecules are useful for

15 diagnosis of disorders associated with aberrant expression of huchordin. Huchordin nucleic acid molecules are also useful in genetic mapping and chromosome identification.

Huchordin Polypeptides

20 The huchordin polypeptides described herein are those encoded by any of the nucleic acid molecules described above and include huchordin fragments, mutants, truncated forms, and fusion proteins. These polypeptides can be prepared for a variety of uses, including but not

25 limited to the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular gene products or compounds that can modulate the activity or expression of huchordin, and as pharmaceutical reagents useful for the treatment of

30 disorders associated with aberrant expression or activity of huchordin.

Preferred polypeptides are substantially pure huchordin polypeptides, including those that correspond to the polypeptide with and without intact signal

35 sequence Especially preferred are huchordin polypeptides that are soluble under normal physiological conditions.

-26-

The invention also encompasses polypeptides that are functionally equivalent to huchordin. These polypeptides are equivalent to huchordin in that they are capable of carrying out one or more of the functions of huchordin in a biological system. Preferred huchordin polypeptides have 20%, 40%, 50%, 75%, 80%, or even 90% of one or more of the biological activities of the full-length, mature human form of huchordin. Such comparisons are generally based on an assay of biological activity in which equal concentrations of the polypeptides are used and compared. The comparison can also be based on the amount of the polypeptide required to reach 50% of the maximal stimulation obtainable.

Functionally equivalent proteins can be those, for example, that contain additional or substituted amino acid residues. Substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. Amino acids that are typically considered to provide a conservative substitution for one another are specified in the summary of the invention.

Polypeptides that are functionally equivalent to huchordin can be made using random mutagenesis techniques well known to those skilled in the art (and the resulting mutant huchordin proteins can be tested for activity). It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis (again using techniques well known to those skilled in the art). These polypeptides may have increased functionality or decreased functionality.

To design functionally equivalent polypeptides, it is useful to distinguish between conserved positions and variable positions. This can be done by aligning the sequence of huchordin cDNAs that were obtained from various organisms. Conserved residues can also be

-27-

identified by aligning motifs within huchordin. For example, the cys residues of the cys-rich repeats are conserved residues. Skilled artisans will recognize that conserved amino acid residues are more likely to be
5 necessary for preservation of function. Thus, it is preferable that conserved residues are not altered.

Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic
10 nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine,
15 asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

Mutations within the huchordin coding sequence can
20 be made to generate variant huchordin genes that are better suited for expression in a selected host cell. For example, N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and
25 purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur (in N-X-S
30 or N-X--), and/or an amino acid deletion at the second position of any one or more of such recognition sequences, will prevent glycosylation at the modified tripeptide sequence (see, for example, Miyajima et al., *EMBO J.* 5:1193, 1986).

35 The polypeptides of the invention can be expressed fused to another polypeptide, for example, a marker

-28-

polypeptide or fusion partner. Alternatively, a fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows
5 for the ready purification of non-denatured fusion proteins expressed in human cell lines (*Proc. Natl. Acad. Sci. USA* 88: 8972-8976, 1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is
10 translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni^{2+} -nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-
15 containing buffers.

The polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., NY, 1983), or, perhaps more advantageously, produced by
20 recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Ausubel et al. (*supra*), Sambrook et al. ("Molecular Cloning, A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of
25 chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984).

Once the recombinant huchordin protein is expressed, it is isolated. Secreted forms can be isolated from the culture media, while non-secreted forms must be isolated
30 from the host cells. Proteins can be isolated by affinity chromatography. In one example, an anti-huchordin protein antibody (e.g., produced as described herein) is attached to a column and used to isolate the huchordin protein. Lysis and fractionation of huchordin
35 protein-harboring cells prior to affinity chromatography can be performed by standard methods (see, e.g., Ausubel

-29-

et al., supra). Alternatively, a huchordin fusion protein, for example, a huchordin-maltose binding protein, a huchordin- β -galactosidase, or a huchordin-trpE fusion protein, can be constructed and used for huchordin
5 protein isolation (see, e.g., Ausubel et al., supra; New England Biolabs, Beverly, MA).

Once isolated, the recombinant protein can, if desired, be further purified, e.g., by high performance liquid chromatography using standard techniques (see,
10 e.g., Fisher, *Laboratory Techniques In Biochemistry And Molecular Biology*, eds., Work and Burdon, Elsevier, 1980).

The invention also features polypeptides that interact with huchordin (and the genes that encode them)
15 and thereby alter the function of huchordin. Interacting polypeptides can be identified using methods known to those skilled in the art. One suitable method is the "two-hybrid system," which detects protein interactions in vivo (Chien et al., *Proc. Natl. Acad. Sci. USA*,
20 88:9578, 1991). A kit for practicing this method is available from Clontech (Palo Alto, CA).

Transgenic animals

Huchordin polypeptides can also be expressed in transgenic animals. These animals represent a model
25 system for the study of disorders that are caused by or exacerbated by overexpression or underexpression of huchordin, and for the development of therapeutic agents that modulate the expression or activity of huchordin.

Transgenic animals can be farm animals (pigs, goats,
30 sheep, cows, horses, rabbits, and the like) rodents (such as rats, guinea pigs, and mice), non-human primates (for example, baboons, monkeys, and chimpanzees), and domestic animals (for example, dogs and cats). Transgenic mice are especially preferred.

35 Any technique known in the art can be used to introduce a huchordin transgene into animals to produce

-30-

the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82:6148, 1985); gene targeting into embryonic stem cells (Thompson et al., *Cell* 56:313, 1989); and electroporation of embryos (Lo, *Mol. Cell. Biol.* 3:1803, 1983).

The present invention provides for transgenic animals that carry a the huchordin transgene in all their cells, as well as animals that carry a transgene in some, but not all of their cells. That is, the invention provides for mosaic animals. The transgene can be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene can also be selectively introduced into and activated in a particular cell type (Lasko et al., *Proc. Natl. Acad. Sci. USA* 89:6232, 1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that the huchordin transgene be integrated into the chromosomal site of the endogenous huchordin the endogenous, gene targeting is preferred. Briefly, when such a technique is to be used, vectors containing some nucleotide sequences homologous to an endogenous huchordin gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene also can be selectively introduced into a particular cell type, thus inactivating the endogenous huchordin gene in only that cell type (Gu et al., *Science* 265:103, 1984). The regulatory sequences required for such a cell-type specific inactivation will depend upon

-31-

the particular cell type of interest, and will be apparent to those of skill in the art. These techniques are useful for preparing "knock outs" having no functional huchordin gene.

5 Once transgenic animals have been generated, the expression of the recombinant huchordin gene can be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to determine whether integration of the
10 transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization
15 analysis, and RT-PCR. Samples of huchordin gene-expressing tissue can also be evaluated immunocytochemically using antibodies specific for the huchordin transgene product.

For a review of techniques that can be used to
20 generate and assess transgenic animals, skilled artisans can consult Gordon (*Intl. Rev. Cytol.* 115:171-229, 1989), and may obtain additional guidance from, for example: Hogan et al., "Manipulating the Mouse Embryo," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1986;
25 Krimpenfort et al., *Bio/Technology* 9:86, 1991; Palmiter et al., *Cell* 41:343, 1985; Kraemer et al., "Genetic Manipulation of the Early Mammalian Embryo," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1985; Hammer et al., *Nature* 315:680, 1985; Purcel et al., *Science*,
30 244:1281, 1986; Wagner et al., U.S. Patent No. 5,175,385; and Krimpenfort et al., U.S. Patent No. 5,175,384 (the latter two publications are hereby incorporated by reference).

Anti-huchordin Antibodies

35 Huchordin polypeptides (or immunogenic fragments or analogs) can be used to raise antibodies useful in the

-32-

invention; such polypeptides can be produced by recombinant techniques or synthesized (see, for example, "Solid Phase Peptide Synthesis," *supra*; Ausubel et al., *supra*). In general, the peptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., *supra*, mixed with an adjuvant, and injected into a host mammal. Antibodies can be purified by peptide antigen affinity chromatography.

In particular, various host animals can be immunized by injection with a huchordin protein or polypeptide. Host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants that can be used to increase the immunological response depend on the host species and include Freund's adjuvant (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Potentially useful human adjuvants include BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules that are contained in the sera of the immunized animals.

Antibodies within the invention therefore include polyclonal antibodies and, in addition, monoclonal antibodies, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, and molecules produced using a Fab expression library.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be prepared using the huchordin polypeptides described above and standard hybridoma technology (see, for example, Kohler et al., *Nature* 256:495, 1975; Kohler et al., *Eur. J. Immunol.* 6:511, 1976; Kohler et al., *Eur. J. Immunol.* 6:292, 1976; Hammerling et al., "Monoclonal Antibodies and T Cell Hybridomas," Elsevier, NY, 1981; Ausubel et al., *supra*).

-33-

In particular, monoclonal antibodies can be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture such as described in Kohler et al., *Nature* 256:495, 1975, and U.S. Patent No. 4,376,110; the human B-cell hybridoma technique (Kosbor et al., *Immunology Today* 4:72, 1983; Cole et al., *Proc. Natl. Acad. Sci. USA* 80:2026, 1983), and the EBV-hybridoma technique (Cole et al., "Monoclonal Antibodies and Cancer Therapy," Alan R. Liss, Inc., pp. 77-96, 1983). Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated *in vitro* or *in vivo*. The ability to produce high titers of mAbs *in vivo* makes this a particularly useful method of production.

Once produced, polyclonal or monoclonal antibodies are tested for specific huchordin recognition by Western blot or immunoprecipitation analysis by standard methods, e.g., as described in Ausubel et al., *supra*. Antibodies that specifically recognize and bind to huchordin are useful in the invention. For example, such antibodies can be used in an immunoassay to monitor the level of huchordin produced by a mammal (for example, to determine the amount or subcellular location of huchordin).

Preferably, antibodies of the invention are produced using fragments of the huchordin protein which lie outside highly conserved regions and appear likely to be antigenic, by criteria such as high frequency of charged residues. In one specific example, such fragments are generated by standard techniques of PCR, and are then cloned into the pGEX expression vector (Ausubel et al., *supra*). Fusion proteins are expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., *supra*.

-34-

Antisera is also checked for its ability to immunoprecipitate recombinant huchordin proteins or control proteins, such as glucocorticoid receptor, CAT, or luciferase.

- 5 The antibodies can be used, for example, in the detection of the huchordin in a biological sample as part of a diagnostic assay. Antibodies also can be used in a screening assay to measure the effect of a candidate compound on expression or localization of huchordin.
- 10 Additionally, such antibodies can be used in conjunction with the gene therapy techniques to, for example, evaluate the normal and/or engineered huchordin-expressing cells prior to their introduction into the patient. Such antibodies additionally can be used in a
- 15 method for inhibiting abnormal huchordin activity.

 In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., *Proc. Natl. Acad. Sci. USA*, 81:6851, 1984; Neuberger et al., *Nature*, 312:604, 1984; Takeda et al., *Nature*, 314:452, 1984) by

20 splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different

25 animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

 Alternatively, techniques described for the production of single chain antibodies (U.S. Patent Nos.

30 4,946,778, 4,946,778, and 4,704,692) can be adapted to produce single chain antibodies against a huchordin protein or polypeptide. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a

35 single chain polypeptide.

-35-

Antibody fragments that recognize and bind to specific epitopes can be generated by known techniques. For example, such fragments include but are not limited to $F(ab')_2$ fragments that can be produced by pepsin digestion of the antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of $F(ab')_2$ fragments. Alternatively, Fab expression libraries can be constructed (Huse et al., *Science*, 246:1275, 1989) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to huchordin can, in turn, be used to generate anti-idiotypic antibodies that resemble a portion of huchordin using techniques well known to those skilled in the art (see, e.g., Greenspan et al., *FASEB J.* 7:437, 1993; Nissinoff, *J. Immunol.* 147:2429, 1991). For example, antibodies that bind to huchordin and competitively inhibit the binding of a binding partner of huchordin can be used to generate anti-idiotypic antibodies that resemble a binding partner binding domain of huchordin and, therefore, bind and neutralize a binding partner of huchordin. Such neutralizing anti-idiotypic antibodies or Fab fragments of such anti-idiotypic antibodies can be used in therapeutic regimens.

Antibodies can be humanized by methods known in the art. For example, monoclonal antibodies with a desired binding specificity can be commercially humanized (Scotgene, Scotland; Oxford Molecular, Palo Alto, CA). Fully human antibodies, such as those expressed in transgenic animals are also features of the invention (Green et al., *Nature Genetics* 7:13-21, 1994; see also U.S. Patents 5,545,806 and 5,569,825, both of which are hereby incorporated by reference).

The methods described herein in which anti-huchordin antibodies are employed may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific huchordin nucleotide sequence or

-36-

antibody reagent described herein, which may be conveniently used, for example, in clinical settings, to diagnose patients exhibiting symptoms of the disorders described below.

5 Antisense Nucleic Acids

Treatment regimes based on an "antisense" approach involve the design of oligonucleotides (either DNA or RNA) that are complementary to huchordin mRNA. These oligonucleotides bind to the complementary huchordin mRNA
10 transcripts and prevent translation. Absolute complementarity, although preferred, is not required. A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA,
15 forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense
20 nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard
25 procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work
30 most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs recently have been shown to be effective at inhibiting translation of mRNAs as well (Wagner, *Nature* 372:333, 1984). Thus, oligonucleotides complementary to
35 either the 5' or 3' non-translated, non-coding regions of the huchordin gene, e.g., the human gene shown in Fig. 1

-37-

could be used in an antisense approach to inhibit translation of endogenous huchordin mRNA.

Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the
5 AUG start codon.

Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the
10 5', 3', or coding region of huchordin mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least
15 17 nucleotides, at least 25 nucleotides, or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that in vitro studies are first performed to quantitate the ability of the antisense oligonucleotide
20 to inhibit gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It is also preferred that these studies compare levels of the target RNA or protein
25 with that of an internal control RNA or protein.

Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of
30 approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

35 The oligonucleotides can be DNA or RNA or PNA or chimeric mixtures or derivatives or modified versions

-38-

thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The

5 oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (as described, e.g., in Letsinger et al., *Proc. Natl. Acad. Sci. USA* 86:6553, 1989; Lemaitre

10 et al., *Proc. Natl. Acad. Sci. USA* 84:648, 1987; PCT Publication No. WO 88/09810) or the blood-brain barrier (see, for example, PCT Publication No. WO 89/10134), or hybridization-triggered cleavage agents (see, for example, Krol et al., *BioTechniques* 6:958, 1988), or

15 intercalating agents (see, for example, Zon, *Pharm. Res.* 5:539, 1988). To this end, the oligonucleotide can be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent.

20 The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-

25 (carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine,

30 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil,

35 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,

-39-

2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 2-(3-amino-3-N-2-carboxypropyl) uracil, 5. (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

10 In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a 15 phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal, or an analog of any of these backbones.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An 20 α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier et al., *Nucl. Acids. Res.* 15:6625, 1987). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue 25 et al., *Nucl. Acids Res.* 15:6131, 1987), or a chimeric RNA-DNA analog (Inoue et al., *FEBS Lett.* 215:327, 1987).

Peptide nucleic acid (PNA) oligonucleotides can be used as antisense molecules (Hyrup et al., *Bioorganic & Medicinal Chem.* 4:5, 1996).

30 Antisense oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate 35 oligonucleotides can be synthesized by the method of Stein et al. (*Nucl. Acids Res.* 16:3209, 1988), and

-40-

methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., *Proc. Natl. Acad. Sci. USA* 85:7448, 1988).

While antisense nucleotides complementary to the
5 huchordin coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

The antisense molecules should be delivered to cells that express huchordin *in vivo*. A number of methods have
10 been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense linked to peptides or antibodies that specifically bind
15 receptors or antigens expressed on the target cell surface) can be administered systemically.

However, it is often difficult to achieve intracellular concentrations of the antisense molecule sufficient to suppress translation of endogenous mRNAs.
20 Therefore, a preferred approach uses a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong *pol* III or *pol* II promoter. The use of such a construct to transfect target cells in the patient will result in the
25 transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous huchordin transcripts and thereby prevent translation of the huchordin mRNA. For example, a vector can be introduced *in vivo* such that it is taken up by a
30 cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.

Such vectors can be constructed by recombinant DNA
35 technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for

-41-

replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible
5 or constitutive. Such promoters include, but are not limited to: the SV40 early promoter region (Bernoist et al., *Nature* 290:304, 1981); the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell* 22:787-797, 1988); the herpes
10 thymidine kinase promoter (Wagner et al., *Proc. Natl. Acad. Sci. USA* 78:1441, 1981); or the regulatory sequences of the metallothionein gene (Brinster et al., *Nature* 296:39, 1988).

Ribozymes

15 Ribozyme molecules designed to catalytically cleave huchordin mRNA transcripts also can be used to prevent translation of huchordin mRNA and expression of huchordin (see, e.g., PCT Publication WO 90/11364; Saraver et al., *Science* 247:1222, 1990). While various ribozymes that
20 cleave mRNA at site-specific recognition sequences can be used to destroy huchordin mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole
25 requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art (Haseloff et al., *Nature* 334:585, 1988). There are numerous examples of potential hammerhead ribozyme
30 cleavage sites within the nucleotide sequence of human huchordin cDNA. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the huchordin mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of
35 non-functional mRNA transcripts.

-42-

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes"), such as the one that occurs naturally in *Tetrahymena Thermophila* (known as the IVS or L-19 IVS RNA), and which has been extensively described by Cech and his collaborators (Zaug et al., *Science* 224:574, 1984; Zaug et al., *Science*, 231:470, 1986; Zug et al., *Nature* 324:429, 1986; PCT Application No. WO 88/04300; and Been et al., *Cell* 47:207, 1986). The Cech-type ribozymes have an eight base-pair sequence that hybridizes to a target RNA sequence, whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes that target eight base-pair active site sequences present in huchordin.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.), and should be delivered to cells which express the huchordin *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive *pol* III or *pol* II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous huchordin messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Methods for Reducing Huchordin Expression

A variety of methods can be used to reduce huchordin expression. For example, the antisense techniques described above can be used to reduce huchordin expression.

Endogenous huchordin gene expression can also be reduced by inactivating or "knocking out" the huchordin gene or its promoter using targeted homologous recombination (see, e.g., U.S. Patent No. 5,464,764). For example, a mutant, non-functional huchordin (or a

-43-

completely unrelated DNA sequence) flanked by DNA homologous to the endogenous huchordin gene (either the coding regions or regulatory regions of the huchordin gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express huchordin *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the huchordin gene. Such approaches are particularly suited for use in the agricultural field where modifications to ES (embryonic stem) cells can be used to generate animal offspring with an inactive huchordin. However, this approach can be adapted for use in humans, provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors.

Alternatively, endogenous huchordin gene expression can be reduced using deoxyribonucleotide sequences complementary to the regulatory region of the huchordin gene (i.e., the huchordin promoter and/or enhancers) to form triple helical structures that prevent transcription of the huchordin gene in target cells in the body (Helene *Anticancer Drug Res.* 6:569, 1981; Helene et al., *Ann. N.Y. Acad. Sci.* 660:27, 1992; and Maher, *Bioassays* 14:807, 1992) or through the use of small molecules which interfere with the expression or activity of transcription factors which regulate *huchordin* expression.

Detecting Proteins Associated with Huchordin

The invention also features polypeptides which interact with huchordin. Any method suitable for detecting protein-protein interactions may be employed for identifying transmembrane proteins, intracellular, or extracellular proteins that interact with huchordin. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell

-44-

lysates or proteins obtained from cell lysates and the use of huchordin to identify proteins in the lysate that interact with huchordin. For these assays, the huchordin polypeptide can be a full length huchordin, a soluble
5 extracellular domain of huchordin, or some other suitable huchordin polypeptide. Once isolated, such an interacting protein can be identified and cloned and then used, in conjunction with standard techniques, to identify proteins with which it interacts. For example,
10 at least a portion of the amino acid sequence of a protein which interacts with the huchordin can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. The amino acid sequence obtained may be used as a guide
15 for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding the interacting protein. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures
20 and the screening are well-known. (Ausubel, *supra*; and "PCR Protocols: A Guide to Methods and Applications," Innis et al., eds. Academic Press, Inc., NY, 1990).

Additionally, methods may be employed which result directly in the identification of genes which encode
25 proteins which interact with huchordin. These methods include, for example, screening expression libraries, in a manner similar to the well known technique of antibody probing of λ gt11 libraries, using labeled huchordin polypeptide or a huchordin fusion protein, e.g., a
30 huchordin polypeptide or domain fused to a marker such as an enzyme, fluorescent dye, a luminescent protein, or to an IgFc domain.

There are also methods which are capable of detecting protein-protein interaction. A method which
35 detects protein interactions *in vivo* is the two-hybrid system (Chien et al., *Proc. Natl. Acad. Sci. USA*,

-45-

88:9578, 1991). A kit for practicing this method is available from Clontech (Palo Alto, CA).

Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one plasmid includes a nucleotide sequence encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding huchordin, a huchordin polypeptide, or a huchordin fusion protein, and the other plasmid includes a nucleotide sequence encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (e.g., HBS or LacZ) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene: the DNA-binding domain hybrid cannot because it does not provide activation function and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system, three-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, huchordin may be used as the bait gene product. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of bait huchordin gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting

-46-

transformants are screened for those that express the reporter gene. For example, a bait huchordin gene sequence, such as huchordin or a domain of huchordin can be cloned into a vector such that it is translationally
5 fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

10 A cDNA library of the cell line from which proteins that interact with bait huchordin gene product are to be detected can be made using methods routinely practiced in the art. According to the particular system described herein, for example, the cDNA fragments can be inserted
15 into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait huchordin gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which
20 contains GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait huchordin gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3
25 can then be purified from these strains, and used to produce and isolate the bait huchordin gene-interacting protein using techniques routinely practiced in the art.

Identification of a Huchordin Receptor

A huchordin receptor can be identified as follows.
30 First cells or tissues which bind huchordin are identified. An expression library is prepared using mRNA isolated from huchordin binding cells. The expression library is used to tranfect, eukaryotic cells, e.g., CHO cells. Detectably labelled huchordin is used to identify
35 clones which bind huchordin. These clones are isolated and purified. The expression plasmid is then isolated

-47-

from the huchordin-binding clones. These expression plasmids will encode putative huchordin receptors.

Identification of Compounds that Modulate the Expression or Activity of Huchordin

5 Isolation of the nucleic acid molecules described above (i.e. those encoding huchordin also facilitates the identification of compounds that can increase or decrease the expression of these molecules *in vivo*. To discover such compounds, cells that express huchordin are
10 cultured, exposed to a test compound (or a mixture of test compounds), and the level of huchordin expression or activity is compared with the level of expression or activity in cells that are otherwise identical but that have not been exposed to the test compound(s). Many
15 standard quantitative assays of gene expression can be utilized in this aspect of the invention. Examples of these assays are provided below.

In order to identify compounds that modulate expression of huchordin (or homologous genes), the
20 candidate compound(s) can be added at varying concentrations to the culture medium of cells that express huchordin, as described above. These compounds can include small molecules, polypeptides, and nucleic acids. The expression of huchordin is then measured, for
25 example, by Northern blot, PCR analyses or RNase protection analyses using a nucleic acid molecule of the invention as a probe. The level of expression of the polypeptides of the invention in the presence of the candidate molecule, compared with their level of
30 expression in its absence, will indicate whether or not the candidate molecule alters the expression of huchordin.

Similarly, compounds that modulate the expression of the polypeptides of the invention can be identified by
35 carrying out the assay described above and then

-48-

performing a Western blot analysis using antibodies that bind huchordin.

Compounds that can be screened in accordance with the invention include, but are not limited to peptides, antibodies and fragments thereof, and other organic compounds (e.g., peptidomimetics).

Such compounds can include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam et al., *Nature* 354:82, 1991; Houghten et al., *Nature* 354:84, 1991), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang et al., *Cell* 72:767, 1993), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂, and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Other compounds that can be screened in accordance with the invention include but are not limited to small organic molecules that affect the expression of the huchordin gene or some other gene involved in a pathway (e.g., signal transduction pathway) involving huchordin (e.g., by interacting with the regulatory region or transcription factors involved in gene expression).

Compounds which Bind Huchordin

Compounds which bind huchordin can be identified using any standard binding assay. The principle of the assays used to identify compounds that bind to huchordin involves preparing a reaction mixture of huchordin and the test compound under conditions and for a time sufficient to allow the two components to interact and

-49-

bind, thus forming a complex which can be removed and/or detected in the reaction mixture.

The screening assays can be conducted in a variety of ways. For example, one method to conduct such an
5 assay would involve anchoring the huchordin protein, polypeptide, peptide or fusion protein or the test substance onto a solid phase and detecting huchordin/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method,
10 huchordin may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component can
15 be immobilized by non-covalent or covalent attachments. Non-covalent attachment can be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the
20 protein to be immobilized can be used to anchor the protein to the solid surface. The surfaces can be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the
25 anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be
30 accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be
35 used to detect complexes anchored on the surface; for example, using a labeled antibody specific for the

-50-

previously nonimmobilized component (the antibody, in turn, can be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; for example, using an immobilized antibody specific for a huchordin protein, polypeptide, peptide or fusion protein or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

Alternatively, cell-based assays can be used to identify compounds that interact with huchordin. To this end, cell lines that express huchordin or cell lines (e.g., COS cells, CHO cells, fibroblasts, etc.) that have been genetically engineered to express huchordin (e.g., by transfection or transduction of huchordin DNA) can be used.

Therapeutic Applications

Huchordin nucleic acid molecules, polypeptides, and huchordin molecules capable of altering huchordin expression, activity, or localization can be used to treat a patient suffering from a disorder associated with aberrant expression or activity huchordin. Such compounds may be used to inhibit fibrosis or angiogenesis.

Diagnostic Applications

The polypeptides of the invention and the antibodies specific for these polypeptides are also useful for identifying those compartments of mammalian cells that contain proteins important to the function of huchordin. Antibodies specific for huchordin can be produced as described above. The normal subcellular location of the protein is then determined either *in situ* or using

-51-

fractionated cells by any standard immunological or immunohistochemical procedure (see, e.g., Ausubel et al., *supra*; Bancroft and Stevens, *Theory and Practice of Histological Techniques*, Churchill Livingstone, 1982).

5 Antibodies specific for huchordin also can be used to detect or monitor huchordin-related diseases. For example, levels of a huchordin protein in a sample can be assayed by any standard technique using these antibodies. For example, huchordin protein expression can be
10 monitored by standard immunological or immunohistochemical procedures (e.g., those described above) using the antibodies described herein. Alternatively, huchordin expression can be assayed by standard Northern blot analysis or can be aided by PCR
15 (see, e.g., Ausubel et al., *supra*; *PCR Technology: Principles and Applications for DNA Amplification*, ed., H.A. Ehrlich, Stockton Press, NY). If desired or necessary, analysis can be carried out to detect point mutations in the huchordin sequence (for example, using
20 well known nucleic acid mismatch detection techniques). All of the above techniques are enabled by the huchordin sequences described herein.

In addition, the present invention encompasses methods and compositions for the diagnostic evaluation,
25 typing, and prognosis of disorders associated with inappropriate expression or activity of huchordin. For example, the nucleic acid molecules of the invention can be used as diagnostic hybridization probes to detect, for example, inappropriate expression of huchordin or
30 mutations in the huchordin gene. Such methods may be used to classify cells by the level of huchordin expression.

Thus, the invention features a method for diagnosing a disorder associated with aberrant activity of
35 huchordin, the method including obtaining a biological sample from a patient and measuring huchordin activity in

-52-

the biological sample, wherein increased or decreased huchordin activity in the biological sample compared to a control indicates that the patient suffers from a disorder associated with aberrant activity of huchordin.

5 High density oligonucleotide probe arrays can be used to detect mutations or polymorphism in the *huchordin* gene. A tiling array (Cronin et al., *Human Mutation* 7:244, 1996; Kozal et al., *Nature Med.* 2:753, 1996) can be used to location mutations anywhere in the gene. A
10 mutation array (Cronin et al., *Human Mutation* 7:244, 1996) can be used to detect the presence of previously identified mutations.

The present invention further provides for diagnostic kits for the practice of such methods.

15 Effective Dose

Toxicity and therapeutic efficacy of the polypeptides of the invention and the compounds that modulate their expression or activity can be determined by standard pharmaceutical procedures, using either cells
20 in culture or experimental animals to determine the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can
25 be expressed as the ratio LD₅₀/ED₅₀. Polypeptides or other compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site
30 of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds
35 lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no

-53-

toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective
5 dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50} (that is, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as
10 determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

Formulations and Use

15 Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

Thus, the compounds and their physiologically
20 acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical
25 compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (for example, pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose);
30 fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (for example, magnesium stearate, talc or silica); disintegrants (for example, potato starch or sodium starch glycolate); or wetting agents (for example, sodium lauryl sulphate).
35 The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may

-54-

take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by
5 conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (for example, lecithin or acacia); non-aqueous vehicles (for example, almond
10 oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (for example, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

15 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in
20 conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a
25 suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to
30 deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral
35 administration by injection, for example, by bolus injection or continuous infusion. Formulations for

-55-

injection may be presented in unit dosage form, for example, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, for example, sterile pyrogen-free water, before use.

10 The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

30 The therapeutic compositions of the invention can also contain a carrier or excipient, many of which are known to skilled artisans. Excipients which can be used include buffers (for example, citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer), amino acids, urea, alcohols, ascorbic acid, phospholipids, proteins (for example, serum albumin), EDTA, sodium

-56-

chloride, liposomes, mannitol, sorbitol, and glycerol. The nucleic acids, polypeptides, antibodies, or modulatory compounds of the invention can be administered by any standard route of administration. For example, 5 administration can be parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, transmucosal, or oral. The modulatory compound can be formulated in various 10 ways, according to the corresponding route of administration. For example, liquid solutions can be made for ingestion or injection; gels or powders can be made for ingestion, inhalation, or topical application. Methods for making such formulations are well known and 15 can be found in, for example, "Remington's Pharmaceutical Sciences." It is expected that the preferred route of administration will be intravenous.

Example

Described below is the identification, sequencing, 20 and characterization of a human huchordin gene.

A novel open reading frame was identified during genomic sequencing of a human bacterial artificial chromosome. The open reading frame was located approximately 4 kb upstream of the thrombopoietin gene. 25 A genomic fragment within the open reading frame was used to probe a human brain cDNA library (Clontech; Palo Alto, CA). A near full-length cDNA clone, lacking only two nucleotides of the initial Met codon, was identified. The identity of the missing nucleotides was confirmed by 30 comparison to the genomic sequence. The cDNA clone encoded a 867 amino acid protein. The cDNA sequence of huchordin is shown in Fig. 1 (SEQ ID NO:1). The huchordin encoding portion of this cDNA extends from nucleotide 1 to nucleotide 2601 (SEQ ID NO:3). The amino

-57-

acid sequence of huchordin is also shown in Fig. 1 (SEQ ID NO:2).

Huchordin is predicted to be a secreted protein having a signal sequence extending from amino acid 1 to amino acid 26. At the amino acid level, huchordin is 53% identical to *Xenopus* chordin (Sasai et al., *Cell* 79:779, 1994). Fig. 3 is an alignment of a portion of the amino acid sequence of huchordin and a portion of the amino acid sequence of *Xenopus* chordin (SEQ ID NO:4). Variants of huchordin which are more likely to retain activity do not have alterations at the amino acid positions conserved between huchordin and chordin.

A human Northern blots (Clontech; Palo Alto, CA) probed with a full-length *huchordin* cDNA clone revealed the presence of an approximately 7.5 kb transcript in adult liver and fetal liver, an approximately 2.7 kb transcript in fetal liver, and an approximately 4.4 kb transcript in brain, heart, and pancreas.

As noted above, huchordin has homology to *Xenopus* chordin, a secreted molecule that functions as a dorsalizing factor in early embryo development. Chordin binds and antagonizes BMP-4, a member of the TGF-beta superfamily.

Huchordin may bind members of the TGF-beta superfamily, e.g., TGF-beta. To the extent that huchordin (or fragments thereof) bind TGF-beta, huchordin can be used to reduce TGF-beta activity, for example, to reduce fibrosis of the kidney, liver, or lung.

The cysteine rich repeats of huchordin are found in thrombospondin-1, thrombospondin-2, and procollagen, protein with anti-angiogenic activity. Thus, huchordin (or fragments thereof which include one or more of the cysteine rich repeats) can be used to inhibit angiogenesis. Such inhibition is useful in limiting tumor growth.

-58-

Deposit Statement

E. coli strain fth66 harboring a *huchordin* cDNA clone was deposited with the American Type Culture Collection on July 2, 1997 and given ATCC Accession No. 5 98481.

This culture has been deposited under conditions that assure that access to the culture will be available during the pendency of the patent application to one determined by the Commissioner of Patents and Trademarks 10 to be entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposit is available as required by foreign patent laws in countries wherein counterparts of the subject application, or its progeny, are filed. However, it should be understood that the availability of the 15 deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by governmental action.

Further, the culture deposit will be stored and made available to the public in accord with the provisions of 20 the Budapest Treaty for the Deposit of Microorganisms, i.e., it will be stored with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposits, and in any case, 25 for a period of at least 30 (thirty) years after the date of deposit or for the enforceable life of any patent which may issue disclosing the culture plus five years after the last request for a sample from the deposit. The depositor acknowledges the duty to replace the 30 deposit should the depository be unable to furnish a sample when requested, due to the condition of the deposit. All restrictions on the availability to the public of the deposit will be irrevocably removed upon the granting of a patent disclosing it.

-59-

What is claimed is:

1. An isolated nucleic acid molecule selected from the group consisting of a nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2 and a nucleic acid molecule which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID NO:3, said hybridizing nucleic acid molecule having the sequence of a naturally-occurring mammalian gene.
2. An isolated nucleic acid molecule encoding amino acids 27-867 of SEQ ID NO:2.
3. An isolated nucleic acid molecule encoding a polypeptide having sequence that is at least 85% identical to the sequence of SEQ ID NO:2.
4. An isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID NO:2.
5. The isolated nucleic acid molecule of claim 1, the molecule comprising the nucleotide sequence of SEQ ID NO:3.
6. The isolated nucleic acid molecule of claim 1, the molecule hybridizing under stringent conditions to a nucleic acid molecule having the sequence of SEQ ID NO:3 or its complement.
7. The isolated nucleic acid molecule of claim 1 comprising the protein coding portion of the huchordin gene contained in A.T.C.C. Deposit No. 98481.

-60-

8. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule hybridized to the nucleotide sequence of the protein coding portion of the huchordin gene contained in A.T.C.C. Deposit No. 5 98481.
9. A host cell comprising the isolated nucleic acid molecule of claim 1.
10. A nucleic acid vector comprising the nucleic acid molecule of claim 1.
- 10 11. The nucleic acid vector of claim 10, wherein the vector is an expression vector.
12. The vector of claim 11, further comprising a regulatory element.
13. The vector of claim 12, wherein the regulatory 15 element is selected from the group consisting of the cytomegalovirus hCMV immediate early gene, the early promoter of SV25 adenovirus, the late promoter of SV25 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter 20 regions of phage λ , the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.
14. The vector of claim 12, wherein the regulatory 25 element directs tissue-specific expression.
15. The vector of claim 11, further comprising a reporter gene.

-61-

16. The vector of claim 15, wherein the reporter gene is selected from the group consisting of β -lactamase, chloramphenicol acetyltransferase (CAT), adenosine deaminase (ADA), aminoglycoside
- 5 phosphotransferase (nec^r , G403 r), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (TK), lacZ (encoding β -galactosidase), and xanthine guanine phosphoribosyltransferase (XGPRT).
17. The vector of claim 10, wherein the vector is a
- 10 plasmid.
18. The vector of claim 10, wherein said vector is a virus.
19. The vector of claim 18, wherein said virus is a retrovirus.
- 15 20. A substantially pure polypeptide selected from the group consisting of a polypeptide having the sequence of SEQ ID NO:2 and a polypeptide encoded by a nucleic molecule which hybridizes under stringent conditions to the nucleic acid molecule of SEQ ID NO:3, said
- 20 hybridizing nucleic acid molecule having the sequence of a naturally-occurring mammalian gene.
21. The polypeptide of claim 20, wherein the polypeptide being soluble under physiological conditions.
22. The polypeptide of claim 20, said polypeptide
- 25 comprising an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NO:2.
23. The polypeptide of claim 20, said polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:2.

-62-

24. The polypeptide of claim 20, said polypeptide comprising an amino acid sequence that is identical to the amino acid sequence of SEQ ID NO:2.

25. The polypeptide of claim 20, wherein the
5 polypeptide comprises the cyteine-rich domains of huchordin.

26. A substantially pure polypeptide comprising a first portion and a second portion, said first portion comprising a huchordin polypeptide and said second
10 portion comprising a detectable marker.

27. An antibody that specifically binds to a huchordin polypeptide.

28. The antibody of claim 27, wherein said antibody is a monoclonal antibody.

15 29. A pharmaceutical composition comprising the polypeptide of claim 20.

30. A method for detecting huchordin in a sample, said method comprising:

- (a) obtaining a biological sample;
- 20 (b) contacting said biological sample with an antibody that specifically binds huchordin under conditions that allow the formation of huchordin-antibody complexes; and
- (c) detecting said complexes, if any, as an
25 indication of the presence of huchordin in said sample.

-63-

31. A method of identifying a compound that modulates the expression of huchordin, said method comprising comparing the level of expression of huchordin in a cell in the presence and absence of a selected
5 compound, wherein a difference in the level of expression in the presence and absence of said selected compound indicates that said selected compound modulates the expression of huchordin.

32. A method of identifying a compound that
10 modulates the activity of huchordin, said method comprising comparing the level of activity of huchordin in a cell in the presence and absence of a selected compound, wherein a difference in the level of activity in the presence and absence of said selected compound
15 indicates that said selected compound modulates the activity of huchordin.

33. A method for treating a patient suffering from a disorder associated with excessive expression or activity of huchordin, comprising administering to said
20 patient a compound which inhibits expression or activity of huchordin.

34. A method for treating a patient suffering from a disorder associated with insufficient expression or activity of huchordin, comprising administering to said
25 patient a compound which increases expression or activity of huchordin.

-64-

35. A method for diagnosing a disorder associated with aberrant expression of huchordin, comprising obtaining a biological sample from a patient and measuring huchordin expression in said biological sample,
5 wherein increased or decreased huchordin expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of huchordin.

36. A method for diagnosing a disorder associated
10 with aberrant activity of huchordin, comprising obtaining a biological sample from a patient and measuring huchordin activity in said biological sample, wherein increased or decreased huchordin activity in said biological sample compared to a control indicates that
15 said patient suffers from a disorder associated with aberrant activity of huchordin.

37. An isolated nucleic acid molecule which hybridizes to a nucleic acid molecule having the sequence of nucleotides 182 to 850, inclusive, of SEQ ID NO:1 or
20 its complement.

38. An isolated nucleic acid molecule having a sequence which is at least 95% identical to the sequence of nucleotides 182 to 850, inclusive of SEQ ID NO:1.

39. A polypeptide encoded by the nucleic acid
25 molecule of any of claims 34 or 35.

M P S L P A P P A P L L L L G L L L L G	20
ATG CCG AGC CTC CCG GCC CCG CCG GCC CCG CTG CTG CTC CTC GGG CTG CTG CTG CTC GGC	50
S R P A R G A G P E P P V L' P I R S E K	40
TCC CCG CCG GCC CCG GCC GCC GCC CCA GAG CCC CCC GTG CTG CCC ATC CGT TCT GAG AAG	120
E P L P V R G A A G C T F G G K V Y A L	60
GAG CCG CTG CCC GTT CCG GGA GCG GCA GGC TGC ACC TTC GGC GGG AAG GTC TAT GCC TTG	180
D E T W H P D L G E P F G V M R C V L C	80
GAC GAG ACG TGG CAC CCG GAC CTA GGG GAG CCA TTC GGG GTG ATG CGC TGC CTG CTG TGC	240
A C E A P Q W G R R T R G P G R V S C K	100
GCC TGC GAG CCG CCT CAG TGG GGT CCG CGT ACC AGG GGC CCT GGC AGG GTC AGC TGC AAG	300
N I K F E C P T P A C G Q P R Q L P G H	120
AAC ATC AAA CCA GAG TGC CCA ACC CTG GCC TGT GGG CAG CCG CCC CAG CTG CCG GGA CAC	360
C C Q T C P Q E R S S S E R Q P S G L S	140
TGC TGC CAG ACC TGC CCC CAG GAG CCG AGC AGT TCG GAG CCG CAG CCG AGC GGC CTG TCC	420
F E Y P R D P E H R S Y S D R G E P S A	160
TTC GAG TAT CCG CCG GAC CCG GAG CAT CCG AGT TAT AGC GAC CCG GGG GAG CCA GGC GCT	480
E E R A R G D G H T D F V A L L T G P R	180
GAG GAG CCG GCC CGT GGT GAC GGC CAC ACG GAC TTC GTG GCG CTG CTG ACA GGG CCG AGG	540
S Q A V A R A R V S L L R S S L R F S I	200
TGC CAG GCG GTG GCA CGA GCC CGA GTC TCG CTG CTG CCG TCT AGC CTC CCG TTC TCT ATC	600
S Y R R L D R P T R I R F S D S N G S V	220
TCC TAC AGG CCG CTG GAC CCG CCT ACC AGG ATC CCG TTC TCA GAC TCC AAT GGC AGT GTC	660
L F E H P A A F T Q D G L V C G V W R A	240
CTG TTT GAG CAC CCT GCA GCC CCC ACC CAA GAT GGC CTG GTC TGT GGG GTG TGG CCG GCA	720
V P R L S L R L L R A E Q L H V A L V T	260
GTG CTT CCG TTG TCT CTG CCG CTC CTT AGG GCA GAA CAG CTG CAT GTG GCA CTT GTG ACA	780
L T H P S G E V W G P L I R H R A L A A	280
CTC ACT CAC CCT TCA GGG GAG GTC TGG GGG CCT CTC ATC CCG CAC CCG GCC CTG GCT GCA	840
E T F S A I L T L E G P P Q Q G V G G I	300
GAG ACC TTC AGT GCC ATC CTG ACT CTA GAA GGC CCC CCA CAG CAG GGC GTA GGG GGC ATC	900
T L L T L S D T E D S L H F L L L F R G	320
ACC CTG CTC ACT CTC AGT GAC ACA GAG GAC TCC TTG CAT TTT TTG CTG CTC TTC CGA GGG	960
L L E P R S G G L T Q V P L R L Q I L H	340
CTG CTG GAA CCC AGG AGT GGG GGA CTA ACC CAG GTT CCC TTG AGG CTC CAG ATT CTA CAC	1020
Q G Q L L R E L Q A N V S A Q E P G F A	360
CAG GGG CAG CTA CTG CGA GAA CTT CAG GCC AAT GTC TCA GCC CAG GAA CCA GGC TTT GCT	1080
E V L P N L T V Q E M D W L V L G E L Q	380
GAG GTG CTG CCC AAC CTG ACA GTC CAG GAG ATG GAC TGG CTG GTG CTG GGG GAG CTG CAG	1140

FIG. 1 (1 of 3)

SUBSTITUTE SHEET (RULE 26)

M A L E W A G R P G L R I S G H I A A R 400
ATG GCC CTG GAG TGG GCA GGC AGG CCA GGG CTG CGC ATC AGT GGA CAC ATT GCT GCC AGG 1200

K S C D V L Q S V L C G A D A L I P V Q 420
AAG AGC TGC GAC GTC CTG CAA AGT GTC CTT TGT GGG GCT GAT GCC CTG ATC CCA GTC CAG 1260

T G A A G S A S L T L L G N G S L I Y Q 440
ACG GGT GCT GCC GGC TCA GCC AGC CTC ACG CTG CTA GGA AAT GGC TCC CTG ATC TAT CAG 1320

V Q V V G T S S E V V A M T L E T K P Q 460
GTG CAA GTG GTA GGG ACA AGC AGT GAG GTG GTG GCC ATG ACA CTG GAG ACC AAG CCT CAG 1380

R R D Q R T V L C H M A G L Q P G G H T 480
CGG AGG GAT CAG CGC ACT GTC CTG TGC CAC ATG GCT GGA CTC CAG CCA GGA GGA CAC ACG 1440

A V G I C P G L G A R G A H M L L Q N E 500
GCC GTG GGT ATC TGC CCT GGG CTG GGT GCC CGA GGG GCT CAT ATG CTG CTG CAG AAT GAG 1500

L F L H V G T K D F P D G E L R G H V A 520
CTC TTC CTG AAC GTG GGC ACC AAG GAC TTC CCA GAC GGA GAG CTT CGG GGG CAC GTG GCT 1560

A L P Y C G H S A R H D T L S V P L A G 540
GCC CTG CCC TAC TGT GGG CAT AGC GCC CGC CAT GAC ACG CTG TCC GTG CCC CTA GCA GCA 1620

A L V L P P V K S Q A A G H A W L S L D 560
GCC CTG GTG CTA CCC CCT GTG AAG AGC CAA GCA GCA GGG CAC GCC TGG CTT TCC TTG GAT 1680

T H C H L H Y E V L L A G L G G S E Q G 580
ACC CAC TGT CAC CTG CAC TAT GAA GTG CTG CTG GCT GGG CTT GGT GGC TCA GAA CAA GGC 1740

T V T A H L L G P P G T P G P R R L L K 600
ACT GTC ACT GCC CAC CTC CTT GGG CCT CCT GGA ACG CCA GGG CCT CGG CGG CTG CTG AAG 1800

G F Y G S E A Q G V V K D L E P E L L R 620
GGA TTC TAT GGC TCA GAG GCC CAG GGT GTG GTG AAG GAC CTG GAG CGG GAA CTG CTG CGG 1860

H L A K G M A S L M I T T K G S P R G E 640
CAC CTG GCA AAA GGC ATG GCC TCC CTG ATG ATC ACC ACC AAG GGT AGC CCC AGA GGG GAG 1920

L R G Q R R T V I C D P V V C P P P S C 660
CTC CGA GGG CAG AGA CGA ACG GTG ATC TGT GAC CGG GTG GTG TGC CCA CGG CCC ACC TGC 1980

P H P V Q A P D Q C C P V C P E K Q D V 680
CCA CAC CCG GTG CAG GCT CCC GAC CAG TGC TGC CCT GTT TGC CCT GAG AAA CAA GAT GTC 2040

R D L P G L P R S R D P G E G C Y F D G 700
AGA GAC TTG CCA GGG CTG CCA AGG AGC CGG GAC CCA GGA GAG GGC TGC TAT TTT GAT GGT 2100

D R S W R A A G T R W H P V V P P F G L 720
GAC CGG AGC TGG CGG GCA GCG GGT ACG CGG TGG CAC CCC GTT GTG CCC CCC TTT GGC TTA 2160

I K C A V C T C K G G T G E V H C E K V 740
ATT AAG TGT GCT GTC TGC ACC TGC AAG GGG GGC ACT GGA GAG GTG CAC TGT GAG AAG GTG 2220

Q C P R L A C A Q P V R V N P T D C C K 760
CAG TGT CCC CGG CTG GCC TGT GCC CAG CCT GTG CGT GTC AAC CCC ACC GAC TGC TGC AAA 2280

FIG. 1 (2 of 3)

SUBSTITUTE SHEET (RULE 26)

Q C P V G S G A H P Q L G D P M Q A D G 780
CAG TGT CCA GTG GGG TCG GGG GGC CAC CCC CAG CTG GGG GAC CCC ATG CAG GCT GAT GGG 2340

P R G C R F A G Q W F P E S Q S W H P S 800
CCC CCG GGC TGC CGT TTT GCT GGG CAG TGG TTC CCA GAG AGT CAG AGC TGG CAC CCC TCA 2400

V P P F G E M S C I T C R C G A G V P H 820
GTG CCC CCT TTT GGA GAG ATG AGC TGT ATC ACC TGC AGA TGT GGG GCA GGG GTG CCT CAC 2460

C E R D D C S L P L S C G S G K E S R C 840
TGT GAG CGG GAT GAC TGT TCA CTG CCA CTG TCC TGT GGC TCG GGG AAG GAG AGT CGA TGC 2520

C S R C T A H R R P A P E T R T D P E L 860
TGT TCC CGC TGC ACG GGC CAC CGG CGG CCA GCC CCA GAG ACC AGA ACT GAT CCA GAG CTG 2580

E K E A E G S *
GAG AAA GAA GCC GAA GGC TCT TAG 868
2604

GGAGCAGCCAGAGGGCCAAGTGACCAAGAGCGATGGGSCCTGAGCTGGGGAAGGGGTGGCATCGAGGACCTTCTTGCAATT 2683

CTCCTGTGGGAAGCCCAAGTGCCTTTCTCTCTCTGTCTCTCTCTACTCCCAACCCCACTACCTTTGGGAACCAAGCTC 2762

CACAAGGGGGAGAGGGCAGCTGGGCCAGACCGAGGTACAGCCCACTCCAAGTCTCTGCCCTGCCACCCCTGGGCTCTGTCTC 2841

TTGGAAGCCCCACCCCTTTCTCTCTGTACATAATGTCACTGGCTTGTGGGATTTTAAATTTATCTTCACTCAGCACCA 2920

AGGGCCCCCGACACTCCACTCCTGCTGCCCTGAGCTGAGCAGAGTCATTATTGGAGAGTTTGTATTTATTAACAT 2999

TTCTTTTTCAGTCAAAAAAAAAAAAAAGGGGCGCGC 3037

FIG. 1 (3 of 3)

[illegible]

FIG. 2 (1 of 3)

6/6

GVPHCERDDCSLPLSCGSGKESRCCSRC.....TAHRRPAPETRTDPEL 865
|:::| |::|. . ::::| .|||::| ...: ...|||. .:
GITQCRRQECTGTTCGTGSKRDRCCCTKCKDANQDEDEKVKSDETRTPWSF 941

FIG. 2 (3 of 3)

SUBSTITUTE SHEET (RULE 26)

-1-

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: MILLENNIUM BIOTHERAPEUTICS, INC.

(ii) TITLE OF THE INVENTION: HUCHORDIN AND USES THEREOF

5 (iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Fish & Richardson P.C.

(B) STREET: 225 Franklin Street

10 (C) CITY: Boston

(D) STATE: MA

(E) COUNTRY: USA

(F) ZIP: 02110-2804

(v) COMPUTER READABLE FORM:

15 (A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: Windows95

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

20 (A) APPLICATION NUMBER: PCT/US98/-----

(B) FILING DATE: 28 September 1998

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: U.S. Serial No. 08/938,365

(B) FILING DATE: 26 September 1997

25 (viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Meiklejohn, Ph.D., Anita L.

(B) REGISTRATION NUMBER: 35,283

(C) REFERENCE/DOCKET NUMBER: 09404/040W01

(ix) TELECOMMUNICATION INFORMATION:

30 (A) TELEPHONE: 617/542-5070

(B) TELEFAX: 617/542-8906

(C) TELEX: 200154

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 3037 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

40 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 1...2601

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

45 ATG CCG AGC CTC CCG GCC CCG CCG GCC CCG CTG CTG CTC CTC GGG CTG
Met Pro Ser Leu Pro Ala Pro Pro Ala Pro Leu Leu Leu Leu Gly Leu
1 5 10 15

48

-2-

	CTG	CTG	CTC	GGC	TCC	CGG	CCG	GCC	CGC	GGC	GCC	GGC	CCA	GAG	CCC	CCC	96
	Leu	Leu	Leu	Gly	Ser	Arg	Pro	Ala	Arg	Gly	Ala	Gly	Pro	Glu	Pro	Pro	
				20					25					30			
5	GTG	CTG	CCC	ATC	CGT	TCT	GAG	AAG	GAG	CCG	CTG	CCC	GTT	CGG	GGA	GCG	144
	Val	Leu	Pro	Ile	Arg	Ser	Glu	Lys	Glu	Pro	Leu	Pro	Val	Arg	Gly	Ala	
			35					40					45				
	GCA	GGC	TGC	ACC	TTC	GGC	GGG	AAG	GTC	TAT	GCC	TTG	GAC	GAG	ACG	TGG	192
	Ala	Gly	Cys	Thr	Phe	Gly	Gly	Lys	Val	Tyr	Ala	Leu	Asp	Glu	Thr	Trp	
			50				55					60					
10	CAC	CCG	GAC	CTA	GGG	GAG	CCA	TTC	GGG	GTG	ATG	CGC	TGC	GTG	CTG	TGC	240
	His	Pro	Asp	Leu	Gly	Glu	Pro	Phe	Gly	Val	Met	Arg	Cys	Val	Leu	Cys	
	65					70					75					80	
	GCC	TGC	GAG	GCG	CCT	CAG	TGG	GGT	CGC	CGT	ACC	AGG	GGC	CCT	GGC	AGG	288
15	Ala	Cys	Glu	Ala	Pro	Gln	Trp	Gly	Arg	Arg	Thr	Arg	Gly	Pro	Gly	Arg	
					85					90					95		
	GTC	AGC	TGC	AAG	AAC	ATC	AAA	CCA	GAG	TGC	CCA	ACC	CCG	GCC	TGT	GGG	336
	Val	Ser	Cys	Lys	Asn	Ile	Lys	Pro	Glu	Cys	Pro	Thr	Pro	Ala	Cys	Gly	
				100					105					110			
20	CAG	CCG	CGC	CAG	CTG	CCG	GGA	CAC	TGC	TGC	CAG	ACC	TGC	CCC	CAG	GAG	384
	Gln	Pro	Arg	Gln	Leu	Pro	Gly	His	Cys	Cys	Gln	Thr	Cys	Pro	Gln	Glu	
				115				120					125				
	CGC	AGC	AGT	TCG	GAG	CGG	CAG	CCG	AGC	GGC	CTG	TCC	TTC	GAG	TAT	CCG	432
	Arg	Ser	Ser	Ser	Glu	Arg	Gln	Pro	Ser	Gly	Leu	Ser	Phe	Glu	Tyr	Pro	
				130			135					140					
25	CGG	GAC	CCG	GAG	CAT	CGC	AGT	TAT	AGC	GAC	CGC	GGG	GAG	CCA	GGC	GCT	480
	Arg	Asp	Pro	Glu	His	Arg	Ser	Tyr	Ser	Asp	Arg	Gly	Glu	Pro	Gly	Ala	
	145					150					155					160	
	GAG	GAG	CGG	GCC	CGT	GGT	GAC	GGC	CAC	ACG	GAC	TTC	GTG	GCG	CTG	CTG	528
30	Glu	Glu	Arg	Ala	Arg	Gly	Asp	Gly	His	Thr	Asp	Phe	Val	Ala	Leu	Leu	
					165					170					175		
	ACA	GGG	CCG	AGG	TCG	CAG	GCG	GTG	GCA	CGA	GCC	CGA	GTC	TCG	CTG	CTG	576
	Thr	Gly	Pro	Arg	Ser	Gln	Ala	Val	Ala	Arg	Ala	Arg	Val	Ser	Leu	Leu	
				180					185					190			
35	CGC	TCT	AGC	CTC	CGC	TTC	TCT	ATC	TCC	TAC	AGG	CGG	CTG	GAC	CGC	CCT	624
	Arg	Ser	Ser	Leu	Arg	Phe	Ser	Ile	Ser	Tyr	Arg	Arg	Leu	Asp	Arg	Pro	
			195					200					205				
	ACC	AGG	ATC	CGC	TTC	TCA	GAC	TCC	AAT	GGC	AGT	GTC	CTG	TTT	GAG	CAC	672
	Thr	Arg	Ile	Arg	Phe	Ser	Asp	Ser	Asn	Gly	Ser	Val	Leu	Phe	Glu	His	
			210				215					220					
40	CCT	GCA	GCC	CCC	ACC	CAA	GAT	GGC	CTG	GTC	TGT	GGG	GTG	TGG	CGG	GCA	720
	Pro	Ala	Ala	Pro	Thr	Gln	Asp	Gly	Leu	Val	Cys	Gly	Val	Trp	Arg	Ala	
						230					235					240	
	GTG	CCT	CGG	TTG	TCT	CTG	CGG	CTC	CTT	AGG	GCA	GAA	CAG	CTG	CAT	GTG	768
45	Val	Pro	Arg	Leu	Ser	Leu	Arg	Leu	Leu	Arg	Ala	Glu	Gln	Leu	His	Val	
					245					250					255		
	GCA	CTT	GTG	ACA	CTC	ACT	CAC	CCT	TCA	GGG	GAG	GTC	TGG	GGG	CCT	CTC	816
	Ala	Leu	Val	Thr	Leu	Thr	His	Pro	Ser	Gly	Glu	Val	Trp	Gly	Pro	Leu	
				260					265					270			

-3-

	ATC	CGG	CAC	CGG	GCC	CTG	GCT	GCA	GAG	ACC	TTC	AGT	GCC	ATC	CTG	ACT	864
	Ile	Arg	His	Arg	Ala	Leu	Ala	Ala	Glu	Thr	Phe	Ser	Ala	Ile	Leu	Thr	
			275					280					285				
5	CTA	GAA	GGC	CCC	CCA	CAG	CAG	GGC	GTA	GGG	GGC	ATC	ACC	CTG	CTC	ACT	912
	Leu	Glu	Gly	Pro	Pro	Gln	Gln	Gly	Val	Gly	Gly	Ile	Thr	Leu	Leu	Thr	
		290					295					300					
	CTC	AGT	GAC	ACA	GAG	GAC	TCC	TTG	CAT	TTT	TTG	CTG	CTC	TTC	CGA	GGG	960
	Leu	Ser	Asp	Thr	Glu	Asp	Ser	Leu	His	Phe	Leu	Leu	Leu	Phe	Arg	Gly	
	305					310					315					320	
10	CTG	CTG	GAA	CCC	AGG	AGT	GGG	GGA	CTA	ACC	CAG	GTT	CCC	TTG	AGG	CTC	1008
	Leu	Leu	Glu	Pro	Arg	Ser	Gly	Gly	Leu	Thr	Gln	Val	Pro	Leu	Arg	Leu	
					325					330					335		
15	CAG	ATT	CTA	CAC	CAG	GGG	CAG	CTA	CTG	CGA	GAA	CTT	CAG	GCC	AAT	GTC	1056
	Gln	Ile	Leu	His	Gln	Gly	Gln	Leu	Leu	Arg	Glu	Leu	Gln	Ala	Asn	Val	
				340				345						350			
	TCA	GCC	CAG	GAA	CCA	GGC	TTT	GCT	GAG	GTG	CTG	CCC	AAC	CTG	ACA	GTC	1104
	Ser	Ala	Gln	Glu	Pro	Gly	Phe	Ala	Glu	Val	Leu	Pro	Asn	Leu	Thr	Val	
			355					360					365				
20	CAG	GAG	ATG	GAC	TGG	CTG	GTG	CTG	GGG	GAG	CTG	CAG	ATG	GCC	CTG	GAG	1152
	Gln	Glu	Met	Asp	Trp	Leu	Val	Leu	Gly	Glu	Leu	Gln	Met	Ala	Leu	Glu	
		370					375					380					
	TGG	GCA	GGC	AGG	CCA	GGG	CTG	CGC	ATC	AGT	GGA	CAC	ATT	GCT	GCC	AGG	1200
	Trp	Ala	Gly	Arg	Pro	Gly	Leu	Arg	Ile	Ser	Gly	His	Ile	Ala	Ala	Arg	
	385					390					395					400	
25	AAG	AGC	TGC	GAC	GTC	CTG	CAA	AGT	GTC	CTT	TGT	GGG	GCT	GAT	GCC	CTG	1248
	Lys	Ser	Cys	Asp	Val	Leu	Gln	Ser	Val	Leu	Cys	Gly	Ala	Asp	Ala	Leu	
					405					410					415		
30	ATC	CCA	GTC	CAG	ACG	GGT	GCT	GCC	GGC	TCA	GCC	AGC	CTC	ACG	CTG	CTA	1296
	Ile	Pro	Val	Gln	Thr	Gly	Ala	Ala	Gly	Ser	Ala	Ser	Leu	Thr	Leu	Leu	
				420					425					430			
	GGA	AAT	GGC	TCC	CTG	ATC	TAT	CAG	GTG	CAA	GTG	GTA	GGG	ACA	AGC	AGT	1344
	Gly	Asn	Gly	Ser	Leu	Ile	Tyr	Gln	Val	Gln	Val	Val	Gly	Thr	Ser	Ser	
			435					440					445				
35	GAG	GTG	GTG	GCC	ATG	ACA	CTG	GAG	ACC	AAG	CCT	CAG	CGG	AGG	GAT	CAG	1392
	Glu	Val	Val	Ala	Met	Thr	Leu	Glu	Thr	Lys	Pro	Gln	Arg	Arg	Asp	Gln	
		450					455					460					
	CGC	ACT	GTC	CTG	TGC	CAC	ATG	GCT	GGA	CTC	CAG	CCA	GGA	GGA	CAC	ACG	1440
	Arg	Thr	Val	Leu	Cys	His	Met	Ala	Gly	Leu	Gln	Pro	Gly	Gly	His	Thr	
	465					470					475					480	
40	GCC	GTG	GGT	ATC	TGC	CCT	GGG	CTG	GGT	GCC	CGA	GGG	GCT	CAT	ATG	CTG	1488
	Ala	Val	Gly	Ile	Cys	Pro	Gly	Leu	Gly	Ala	Arg	Gly	Ala	His	Met	Leu	
					485					490					495		
45	CTG	CAG	AAT	GAG	CTC	TTC	CTG	AAC	GTG	GGC	ACC	AAG	GAC	TTC	CCA	GAC	1536
	Leu	Gln	Asn	Glu	Leu	Phe	Leu	Asn	Val	Gly	Thr	Lys	Asp	Phe	Pro	Asp	
				500					505					510			
	GGA	GAG	CTT	CGG	GGG	CAC	GTG	GCT	GCC	CTG	CCC	TAC	TGT	GGG	CAT	AGC	1584
	Gly	Glu	Leu	Arg	Gly	His	Val	Ala	Ala	Leu	Pro	Tyr	Cys	Gly	His	Ser	
			515					520					525				

-4-

	GCC	CGC	CAT	GAC	ACG	CTG	TCC	GTG	CCC	CTA	GCA	GGA	GCC	CTG	GTG	CTA	1632
	Ala	Arg	His	Asp	Thr	Leu	Ser	Val	Pro	Leu	Ala	Gly	Ala	Leu	Val	Leu	
	530						535					540					
5	CCC	CCT	GTG	AAG	AGC	CAA	GCA	GCA	GGG	CAC	GCC	TGG	CTT	TCC	TTG	GAT	1680
	Pro	Pro	Val	Lys	Ser	Gln	Ala	Ala	Gly	His	Ala	Trp	Leu	Ser	Leu	Asp	
	545					550					555					560	
	ACC	CAC	TGT	CAC	CTG	CAC	TAT	GAA	GTG	CTG	CTG	GCT	GGG	CTT	GGT	GGC	1728
	Thr	His	Cys	His	Leu	His	Tyr	Glu	Val	Leu	Leu	Ala	Gly	Leu	Gly	Gly	
					565					570					575		
10	TCA	GAA	CAA	GGC	ACT	GTC	ACT	GCC	CAC	CTC	CTT	GGG	CCT	CCT	GGA	ACG	1776
	Ser	Glu	Gln	Gly	Thr	Val	Thr	Ala	His	Leu	Leu	Gly	Pro	Pro	Gly	Thr	
				580					585					590			
15	CCA	GGG	CCT	CGG	CGG	CTG	CTG	AAG	GGA	TTC	TAT	GGC	TCA	GAG	GCC	CAG	1824
	Pro	Gly	Pro	Arg	Arg	Leu	Leu	Lys	Gly	Phe	Tyr	Gly	Ser	Glu	Ala	Gln	
			595					600					605				
	GGT	GTG	GTG	AAG	GAC	CTG	GAG	CCG	GAA	CTG	CTG	CGG	CAC	CTG	GCA	AAA	1872
	Gly	Val	Val	Lys	Asp	Leu	Glu	Pro	Glu	Leu	Leu	Arg	His	Leu	Ala	Lys	
	610						615					620					
20	GGC	ATG	GCC	TCC	CTG	ATG	ATC	ACC	ACC	AAG	GGT	AGC	CCC	AGA	GGG	GAG	1920
	Gly	Met	Ala	Ser	Leu	Met	Ile	Thr	Thr	Lys	Gly	Ser	Pro	Arg	Gly	Glu	
	625					630					635					640	
	CTC	CGA	GGG	CAG	AGA	CGA	ACG	GTG	ATC	TGT	GAC	CCG	GTG	GTG	TGC	CCA	1968
	Leu	Arg	Gly	Gln	Arg	Arg	Thr	Val	Ile	Cys	Asp	Pro	Val	Val	Cys	Pro	
					645					650					655		
25	CCG	CCC	AGC	TGC	CCA	CAC	CCG	GTG	CAG	GCT	CCC	GAC	CAG	TGC	TGC	CCT	2016
	Pro	Pro	Ser	Cys	Pro	His	Pro	Val	Gln	Ala	Pro	Asp	Gln	Cys	Cys	Pro	
				660					665					670			
30	GTT	TGC	CCT	GAG	AAA	CAA	GAT	GTC	AGA	GAC	TTG	CCA	GGG	CTG	CCA	AGG	2064
	Val	Cys	Pro	Glu	Lys	Gln	Asp	Val	Arg	Asp	Leu	Pro	Gly	Leu	Pro	Arg	
			675					680					685				
	AGC	CGG	GAC	CCA	GGA	GAG	GGC	TGC	TAT	TTT	GAT	GGT	GAC	CGG	AGC	TGG	2112
	Ser	Arg	Asp	Pro	Gly	Glu	Gly	Cys	Tyr	Phe	Asp	Gly	Asp	Arg	Ser	Trp	
	690						695					700					
35	CGG	GCA	GCG	GGT	ACG	CGG	TGG	CAC	CCC	GTT	GTG	CCC	CCC	TTT	GGC	TTA	2160
	Arg	Ala	Ala	Gly	Thr	Arg	Trp	His	Pro	Val	Val	Pro	Pro	Phe	Gly	Leu	
	705					710					715					720	
	ATT	AAG	TGT	GCT	GTC	TGC	ACC	TGC	AAG	GGG	GGC	ACT	GGA	GAG	GTG	CAC	2208
	Ile	Lys	Cys	Ala	Val	Cys	Thr	Cys	Lys	Gly	Gly	Thr	Gly	Glu	Val	His	
					725					730					735		
40	TGT	GAG	AAG	GTG	CAG	TGT	CCC	CGG	CTG	GCC	TGT	GCC	CAG	CCT	GTG	CGT	2256
	Cys	Glu	Lys	Val	Gln	Cys	Pro	Arg	Leu	Ala	Cys	Ala	Gln	Pro	Val	Arg	
				740					745					750			
45	GTC	AAC	CCC	ACC	GAC	TGC	TGC	AAA	CAG	TGT	CCA	GTG	GGG	TCG	GGG	GCC	2304
	Val	Asn	Pro	Thr	Asp	Cys	Cys	Lys	Gln	Cys	Pro	Val	Gly	Ser	Gly	Ala	
			755					760					765				
	CAC	CCC	CAG	CTG	GGG	GAC	CCC	ATG	CAG	GCT	GAT	GGG	CCC	CGG	GGC	TGC	2352
	His	Pro	Gln	Leu	Gly	Asp	Pro	Met	Gln	Ala	Asp	Gly	Pro	Arg	Gly	Cys	
	770						775					780					

-5-

```

CGT TTT GCT GGG CAG TGG TTC CCA GAG AGT CAG AGC TGG CAC CCC TCA      2400
Arg Phe Ala Gly Gln Trp Phe Pro Glu Ser Gln Ser Trp His Pro Ser
785                               790                               795                               800

5  GTG CCC CCT TTT GGA GAG ATG AGC TGT ATC ACC TGC AGA TGT GGG GCA      2448
Val Pro Pro Phe Gly Glu Met Ser Cys Ile Thr Cys Arg Cys Gly Ala
                               805                               810                               815

GGG GTG CCT CAC TGT GAG CGG GAT GAC TGT TCA CTG CCA CTG TCC TGT      2496
Gly Val Pro His Cys Glu Arg Asp Asp Cys Ser Leu Pro Leu Ser Cys
                               820                               825                               830

10 GGC TCG GGG AAG GAG AGT CGA TGC TGT TCC CGC TGC ACG GCC CAC CGG      2544
Gly Ser Gly Lys Glu Ser Arg Cys Cys Ser Arg Cys Thr Ala His Arg
                               835                               840                               845

CGG CCA GCC CCA GAG ACC AGA ACT GAT CCA GAG CTG GAG AAA GAA GCC      2592
Arg Pro Ala Pro Glu Thr Arg Thr Asp Pro Glu Leu Glu Lys Glu Ala
15                               850                               855                               860

GAA GGC TCT TAGGGAGCAG CCAGAGGGCC AAGTGACCAA GAGGATGGGG CCTGAGCTG      2650
Glu Gly Ser
865

GGGAAGGGGT GGCATCGAGG ACCTTCTTGC ATTCTCCTGT GGGAAGCCCA GTGCCTTTGC
20 2710
TCCTCTGTCC TGCCTCTACT CCCACCCCCA CTACCTTTGG GAACCACAGC TCCACAAGGG
2770
GGAGAGGCAG CTGGGCCAGA CCGAGGTCAC AGCCACTCCA AGTCCTGCCC TGCCACCCCTC
2830
25 GGCCTCTGTC CTTGGAAGCC CCACCCCTTT CCTCCTGTAC ATAATGTCAC TGGCTTGTG
2890
GGATTTTAA TTTATCTTCA CTCAGCACCA AGGGCCCCCG AACTCCACT CCTGCTGCCC
2950
CTGAGCTGAG CAGAGTCATT ATTGGAGAGT TTTGTATTTA TTAAACATT TCTTTTTCAG
30 3010
TCAAAAAAAA AAAAAAAGGG CGGCCGC
3037

```

(2) INFORMATION FOR SEQ ID NO:2:

```

35 (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 867 amino acids
    (B) TYPE: amino acid
    (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: protein

    (v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Pro Ser Leu Pro Ala Pro Pro Ala Pro Leu Leu Leu Leu Gly Leu
  1      5      10      15
Leu Leu Leu Gly Ser Arg Pro Ala Arg Gly Ala Gly Pro Glu Pro Pro
  20      25      30
45 Val Leu Pro Ile Arg Ser Glu Lys Glu Pro Leu Pro Val Arg Gly Ala
  35      40      45
Ala Gly Cys Thr Phe Gly Gly Lys Val Tyr Ala Leu Asp Glu Thr Trp
  50      55      60
His Pro Asp Leu Gly Glu Pro Phe Gly Val Met Arg Cys Val Leu Cys
50 65      70      75      80
Ala Cys Glu Ala Pro Gln Trp Gly Arg Arg Thr Arg Gly Pro Gly Arg
      85      90      95

```

-6-

	Val	Ser	Cys	Lys	Asn	Ile	Lys	Pro	Glu	Cys	Pro	Thr	Pro	Ala	Cys	Gly
				100					105					110		
	Gln	Pro	Arg	Gln	Leu	Pro	Gly	His	Cys	Cys	Gln	Thr	Cys	Pro	Gln	Glu
			115					120					125			
5	Arg	Ser	Ser	Ser	Glu	Arg	Gln	Pro	Ser	Gly	Leu	Ser	Phe	Glu	Tyr	Pro
		130					135					140				
	Arg	Asp	Pro	Glu	His	Arg	Ser	Tyr	Ser	Asp	Arg	Gly	Glu	Pro	Gly	Ala
		145				150				155						160
10	Glu	Glu	Arg	Ala	Arg	Gly	Asp	Gly	His	Thr	Asp	Phe	Val	Ala	Leu	Leu
				165						170					175	
	Thr	Gly	Pro	Arg	Ser	Gln	Ala	Val	Ala	Arg	Ala	Arg	Val	Ser	Leu	Leu
				180					185					190		
	Arg	Ser	Ser	Leu	Arg	Phe	Ser	Ile	Ser	Tyr	Arg	Arg	Leu	Asp	Arg	Pro
		195						200					205			
15	Thr	Arg	Ile	Arg	Phe	Ser	Asp	Ser	Asn	Gly	Ser	Val	Leu	Phe	Glu	His
		210					215					220				
	Pro	Ala	Ala	Pro	Thr	Gln	Asp	Gly	Leu	Val	Cys	Gly	Val	Trp	Arg	Ala
						230					235					240
20	Val	Pro	Arg	Leu	Ser	Leu	Arg	Leu	Leu	Arg	Ala	Glu	Gln	Leu	His	Val
				245						250					255	
	Ala	Leu	Val	Thr	Leu	Thr	His	Pro	Ser	Gly	Glu	Val	Trp	Gly	Pro	Leu
				260					265					270		
	Ile	Arg	His	Arg	Ala	Leu	Ala	Ala	Glu	Thr	Phe	Ser	Ala	Ile	Leu	Thr
			275					280					285			
25	Leu	Glu	Gly	Pro	Pro	Gln	Gln	Gly	Val	Gly	Gly	Ile	Thr	Leu	Leu	Thr
		290					295					300				
	Leu	Ser	Asp	Thr	Glu	Asp	Ser	Leu	His	Phe	Leu	Leu	Leu	Phe	Arg	Gly
		305				310				315						320
30	Leu	Leu	Glu	Pro	Arg	Ser	Gly	Gly	Leu	Thr	Gln	Val	Pro	Leu	Arg	Leu
				325						330					335	
	Gln	Ile	Leu	His	Gln	Gly	Gln	Leu	Leu	Arg	Glu	Leu	Gln	Ala	Asn	Val
				340					345					350		
	Ser	Ala	Gln	Glu	Pro	Gly	Phe	Ala	Glu	Val	Leu	Pro	Asn	Leu	Thr	Val
			355					360					365			
35	Gln	Glu	Met	Asp	Trp	Leu	Val	Leu	Gly	Glu	Leu	Gln	Met	Ala	Leu	Glu
		370					375					380				
	Trp	Ala	Gly	Arg	Pro	Gly	Leu	Arg	Ile	Ser	Gly	His	Ile	Ala	Ala	Arg
		385				390				395						400
40	Lys	Ser	Cys	Asp	Val	Leu	Gln	Ser	Val	Leu	Cys	Gly	Ala	Asp	Ala	Leu
				405						410					415	
	Ile	Pro	Val	Gln	Thr	Gly	Ala	Ala	Gly	Ser	Ala	Ser	Leu	Thr	Leu	Leu
				420					425					430		
	Gly	Asn	Gly	Ser	Leu	Ile	Tyr	Gln	Val	Gln	Val	Val	Gly	Thr	Ser	Ser
			435					440					445			
45	Glu	Val	Val	Ala	Met	Thr	Leu	Glu	Thr	Lys	Pro	Gln	Arg	Arg	Asp	Gln
		450					455					460				
	Arg	Thr	Val	Leu	Cys	His	Met	Ala	Gly	Leu	Gln	Pro	Gly	Gly	His	Thr
		465				470				475						480
50	Ala	Val	Gly	Ile	Cys	Pro	Gly	Leu	Gly	Ala	Arg	Gly	Ala	His	Met	Leu
				485						490					495	
	Leu	Gln	Asn	Glu	Leu	Phe	Leu	Asn	Val	Gly	Thr	Lys	Asp	Phe	Pro	Asp
				500					505					510		
	Gly	Glu	Leu	Arg	Gly	His	Val	Ala	Ala	Leu	Pro	Tyr	Cys	Gly	His	Ser
			515					520					525			
55	Ala	Arg	His	Asp	Thr	Leu	Ser	Val	Pro	Leu	Ala	Gly	Ala	Leu	Val	Leu
		530					535					540				
	Pro	Pro	Val	Lys	Ser	Gln	Ala	Ala	Gly	His	Ala	Trp	Leu	Ser	Leu	Asp
		545				550				555						560
60	Thr	His	Cys	His	Leu	His	Tyr	Glu	Val	Leu	Leu	Ala	Gly	Leu	Gly	Gly
				565						570					575	
	Ser	Glu	Gln	Gly	Thr	Val	Thr	Ala	His	Leu	Leu	Gly	Pro	Pro	Gly	Thr
				580					585					590		
	Pro	Gly	Pro	Arg	Arg	Leu	Leu	Lys	Gly	Phe	Tyr	Gly	Ser	Glu	Ala	Gln
			595					600					605			

-7-

Gly Val Val Lys Asp Leu Glu Pro Glu Leu Leu Arg His Leu Ala Lys
 610 615 620
 Gly Met Ala Ser Leu Met Ile Thr Thr Lys Gly Ser Pro Arg Gly Glu
 625 630 635 640
 5 Leu Arg Gly Gln Arg Arg Thr Val Ile Cys Asp Pro Val Val Cys Pro
 645 650 655
 Pro Pro Ser Cys Pro His Pro Val Gln Ala Pro Asp Gln Cys Cys Pro
 660 665 670
 10 Val Cys Pro Glu Lys Gln Asp Val Arg Asp Leu Pro Gly Leu Pro Arg
 675 680 685
 Ser Arg Asp Pro Gly Glu Gly Cys Tyr Phe Asp Gly Asp Arg Ser Trp
 690 695 700
 Arg Ala Ala Gly Thr Arg Trp His Pro Val Val Pro Pro Phe Gly Leu
 705 710 715 720
 15 Ile Lys Cys Ala Val Cys Thr Cys Lys Gly Gly Thr Gly Glu Val His
 725 730 735
 Cys Glu Lys Val Gln Cys Pro Arg Leu Ala Cys Ala Gln Pro Val Arg
 740 745 750
 20 Val Asn Pro Thr Asp Cys Cys Lys Gln Cys Pro Val Gly Ser Gly Ala
 755 760 765
 His Pro Gln Leu Gly Asp Pro Met Gln Ala Asp Gly Pro Arg Gly Cys
 770 775 780
 Arg Phe Ala Gly Gln Trp Phe Pro Glu Ser Gln Ser Trp His Pro Ser
 785 790 795 800
 25 Val Pro Pro Phe Gly Glu Met Ser Cys Ile Thr Cys Arg Cys Gly Ala
 805 810 815
 Gly Val Pro His Cys Glu Arg Asp Asp Cys Ser Leu Pro Leu Ser Cys
 820 825 830
 30 Gly Ser Gly Lys Glu Ser Arg Cys Cys Ser Arg Cys Thr Ala His Arg
 835 840 845
 Arg Pro Ala Pro Glu Thr Arg Thr Asp Pro Glu Leu Glu Lys Glu Ala
 850 855 860
 Glu Gly Ser
 865

35 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 855 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Ala Pro Pro Ala Pro Leu Leu Leu Leu Gly Leu Leu Leu Leu Gly Ser
 1 5 10 15
 45 Arg Pro Ala Arg Gly Ala Gly Pro Glu Pro Pro Val Leu Pro Ile Arg
 20 25 30
 Ser Glu Lys Glu Pro Leu Pro Val Arg Gly Ala Ala Gly Cys Thr Phe
 35 40 45
 Gly Gly Lys Val Tyr Ala Leu Asp Glu Thr Trp His Pro Asp Leu Gly
 50 55 60
 Glu Pro Phe Gly Val Met Arg Cys Val Leu Cys Ala Cys Glu Ala Pro
 65 70 75 80
 Gln Trp Gly Arg Arg Thr Arg Gly Pro Gly Arg Val Ser Cys Lys Asn
 85 90 95
 55 Ile Lys Pro Glu Cys Pro Thr Pro Ala Cys Gly Gln Pro Arg Gln Leu
 100 105 110
 Pro Gly His Cys Cys Gln Thr Cys Pro Gln Glu Arg Ser Ser Ser Glu
 115 120 125

-8-

	Arg	Gln	Pro	Ser	Gly	Leu	Ser	Phe	Glu	Tyr	Pro	Arg	Asp	Pro	Glu	His
	130						135					140				
	Arg	Ser	Tyr	Ser	Asp	Arg	Gly	Glu	Pro	Gly	Ala	Glu	Glu	Arg	Ala	Arg
	145				150						155					160
5	Gly	Asp	Gly	His	Thr	Asp	Phe	Val	Ala	Leu	Leu	Thr	Gly	Pro	Arg	Ser
					165					170					175	
	Gln	Ala	Val	Ala	Arg	Ala	Arg	Val	Ser	Leu	Leu	Arg	Ser	Ser	Leu	Arg
				180					185					190		
10	Phe	Ser	Ile	Ser	Tyr	Arg	Arg	Leu	Asp	Arg	Pro	Thr	Arg	Ile	Arg	Phe
		195						200					205			
	Ser	Asp	Ser	Asn	Gly	Ser	Val	Leu	Phe	Glu	His	Pro	Ala	Ala	Pro	Thr
		210					215					220				
	Gln	Asp	Gly	Leu	Val	Cys	Gly	Val	Trp	Arg	Ala	Val	Pro	Arg	Leu	Ser
	225					230					235					240
15	Leu	Arg	Leu	Leu	Arg	Ala	Glu	Gln	Leu	His	Val	Ala	Leu	Val	Thr	Leu
					245					250					255	
	Thr	His	Pro	Ser	Gly	Glu	Val	Trp	Gly	Pro	Leu	Ile	Arg	His	Arg	Ala
				260					265					270		
20	Leu	Ala	Ala	Glu	Thr	Phe	Ser	Ala	Ile	Leu	Thr	Leu	Glu	Gly	Pro	Pro
				275				280					285			
	Gln	Gln	Gly	Val	Gly	Gly	Ile	Thr	Leu	Leu	Thr	Leu	Ser	Asp	Thr	Glu
		290					295					300				
	Asp	Ser	Leu	His	Phe	Leu	Leu	Phe	Arg	Gly	Leu	Leu	Glu	Pro	Arg	
	305				310					315						320
25	Ser	Gly	Gly	Leu	Thr	Gln	Val	Pro	Leu	Arg	Leu	Gln	Ile	Leu	His	Gln
					325					330					335	
	Gly	Gln	Leu	Leu	Arg	Glu	Leu	Gln	Ala	Asn	Val	Ser	Ala	Gln	Glu	Pro
				340					345					350		
30	Gly	Phe	Ala	Glu	Val	Leu	Pro	Asn	Leu	Thr	Val	Gln	Glu	Met	Asp	Trp
				355				360					365			
	Leu	Val	Leu	Gly	Glu	Leu	Gln	Met	Ala	Leu	Glu	Trp	Ala	Gly	Arg	Pro
		370					375					380				
	Gly	Leu	Arg	Ile	Ser	Gly	His	Ile	Ala	Ala	Arg	Lys	Ser	Cys	Asp	Val
	385					390					395					400
35	Leu	Gln	Ser	Val	Leu	Cys	Gly	Ala	Asp	Ala	Leu	Ile	Pro	Val	Gln	Thr
				405						410					415	
	Gly	Ala	Ala	Gly	Ser	Ala	Ser	Leu	Thr	Leu	Leu	Gly	Asn	Gly	Ser	Leu
				420					425				430			
40	Ile	Tyr	Gln	Val	Gln	Val	Val	Gly	Thr	Ser	Ser	Glu	Val	Val	Ala	Met
				435				440					445			
	Thr	Leu	Glu	Thr	Lys	Pro	Gln	Arg	Arg	Asp	Gln	Arg	Thr	Val	Leu	Cys
		450					455					460				
	His	Met	Ala	Gly	Leu	Gln	Pro	Gly	Gly	His	Thr	Ala	Val	Gly	Ile	Cys
	465				470					475						480
45	Pro	Gly	Leu	Gly	Ala	Arg	Gly	Ala	His	Met	Leu	Leu	Gln	Asn	Glu	Leu
				485						490					495	
	Phe	Leu	Asn	Val	Gly	Thr	Lys	Asp	Phe	Pro	Asp	Gly	Glu	Leu	Arg	Gly
				500					505				510			
50	His	Val	Ala	Ala	Leu	Pro	Tyr	Cys	Gly	His	Ser	Ala	Arg	His	Asp	Thr
			515					520					525			
	Leu	Ser	Val	Pro	Leu	Ala	Gly	Ala	Leu	Val	Leu	Pro	Pro	Val	Lys	Ser
		530					535					540				
	Gln	Ala	Ala	Gly	His	Ala	Trp	Leu	Ser	Leu	Asp	Thr	His	Cys	His	Leu
	545					550					555					560
55	His	Tyr	Glu	Val	Leu	Leu	Val	Gly	Leu	Gly	Gly	Ser	Glu	Gln	Gly	Thr
					565					570					575	
	Val	Thr	Ala	His	Leu	Leu	Gly	Pro	Pro	Gly	Thr	Pro	Gly	Pro	Arg	Arg
				580					585				590			
60	Leu	Leu	Lys	Gly	Phe	Tyr	Gly	Ser	Glu	Ala	Gln	Gly	Val	Val	Lys	Asp
			595					600					605			
	Leu	Glu	Pro	Glu	Leu	Leu	Arg	His	Leu	Ala	Lys	Gly	Met	Ala	Ser	Leu
		610					615					620				
	Met	Ile	Thr	Thr	Lys	Gly	Ser	Pro	Arg	Gly	Glu	Leu	Arg	Gly	Gln	Arg
	625					630					635					640
65	Arg	Thr	Val	Ile	Cys	Asp	Pro	Val	Val	Cys	Pro	Pro	Pro	Ser	Cys	Pro

-9-

					645					650				655
	His	Pro	Val	Gln	Ala	Pro	Asp	Gln	Cys	Cys	Pro	Val	Cys	Pro
					660					665				670
	Gln	Asp	Val	Arg	Asp	Leu	Pro	Gly	Leu	Pro	Arg	Ser	Arg	Asp
5					675					680				685
	Glu	Gly	Cys	Tyr	Phe	Asp	Gly	Asp	Arg	Ser	Trp	Arg	Ala	Ala
					690					695				700
	Arg	Trp	His	Pro	Val	Val	Pro	Pro	Phe	Gly	Leu	Ile	Lys	Cys
					705					710				715
10	Cys	Thr	Cys	Lys	Gly	Thr	Gly	Glu	Val	His	Cys	Glu	Lys	Val
					725					730				735
	Cys	Pro	Arg	Leu	Ala	Cys	Ala	Gln	Pro	Val	Arg	Val	Asn	Pro
					740					745				750
15	Cys	Cys	Lys	Gln	Cys	Pro	Val	Gly	Ser	Gly	Ala	His	Pro	Gln
					755					760				765
	Asp	Pro	Met	Gln	Ala	Asp	Gly	Pro	Arg	Gly	Cys	Arg	Phe	Ala
					770					775				780
	Trp	Phe	Pro	Glu	Ser	Gln	Ser	Trp	His	Pro	Ser	Val	Pro	Phe
					785					790				800
20	Glu	Met	Ser	Cys	Ile	Thr	Cys	Arg	Cys	Gly	Ala	Gly	Val	Pro
					805					810				815
	Glu	Arg	Asp	Asp	Cys	Ser	Leu	Pro	Leu	Ser	Cys	Gly	Ser	Gly
					820					825				830
	Ser	Arg	Cys	Cys	Ser	Arg	Cys	Thr	Ala	His	Arg	Arg	Pro	Ala
25					835					840				845
	Thr	Arg	Thr	Asp	Pro	Glu	Leu							
					850					855				

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 940 amino acids
(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

35	Gln	Cys	Pro	Pro	Ile	Leu	Leu	Val	Trp	Thr	Leu	Trp	Ile	Met	Ala	Val
	1				5					10					15	
	Asp	Cys	Ser	Arg	Pro	Lys	Val	Phe	Leu	Pro	Ile	Gln	Pro	Glu	Gln	Glu
				20					25					30		
40	Pro	Leu	Gln	Ser	Lys	Thr	Pro	Ala	Gly	Cys	Thr	Phe	Gly	Gly	Lys	Phe
			35					40					45			
	Tyr	Ser	Leu	Glu	Asp	Ser	Trp	His	Pro	Asp	Leu	Gly	Glu	Pro	Phe	Gly
			50				55					60				
	Val	Met	His	Cys	Val	Leu	Cys	Tyr	Cys	Glu	Pro	Gln	Arg	Ser	Arg	Arg
			65			70				75					80	
45	Gly	Lys	Pro	Ser	Gly	Lys	Val	Ser	Cys	Lys	Asn	Ile	Lys	His	Asp	Cys
					85					90					95	
	Pro	Ser	Pro	Ser	Cys	Ala	Asn	Pro	Ile	Leu	Leu	Pro	Leu	His	Cys	Cys
					100				105					110		
	Lys	Thr	Cys	Pro	Lys	Ala	Pro	Pro	Pro	Ile	Lys	Lys	Ser	Asp	Phe	
50			115					120					125			
	Val	Phe	Asp	Gly	Phe	Glu	Tyr	Phe	Gln	Glu	Lys	Asp	Asp	Asp	Leu	Tyr
			130			135						140				
	Asn	Asp	Arg	Ser	Tyr	Leu	Ser	Ser	Asp	Asp	Val	Ala	Val	Glu	Glu	Ser
					145		150			155					160	
55	Arg	Ser	Glu	Tyr	Val	Ala	Leu	Leu	Thr	Ala	Pro	Ser	His	Val	Trp	Pro
					165					170					175	
	Pro	Val	Thr	Ser	Gly	Val	Ala	Lys	Ala	Arg	Phe	Asn	Leu	Gln	Arg	Ser
					180				185					190		

-10-

	Asn	Leu	Leu	Phe	Ser	Ile	Thr	Tyr	Lys	Trp	Ile	Asp	Arg	Leu	Ser	Arg
			195					200					205			
	Ile	Arg	Phe	Ser	Asp	Leu	Asp	Gly	Ser	Val	Leu	Phe	Glu	His	Pro	Val
		210					215					220				
5	His	Arg	Met	Gly	Ser	Pro	Arg	Asp	Asp	Thr	Ile	Cys	Gly	Ile	Trp	Arg
		225				230					235					240
	Ser	Leu	Asn	Arg	Ser	Thr	Leu	Arg	Leu	Leu	Arg	Met	Gly	His	Ile	Leu
					245					250					255	
	Val	Ser	Leu	Val	Thr	Thr	Thr	Leu	Ser	Glu	Pro	Glu	Ile	Ser	Gly	Lys
10					260					265				270		
	Ile	Val	Lys	His	Lys	Ala	Leu	Phe	Ser	Glu	Ser	Phe	Ser	Ala	Leu	Leu
			275					280					285			
	Thr	Pro	Glu	Asp	Ser	Asp	Glu	Thr	Gly	Gly	Gly	Gly	Gly	Leu	Ala	Met
		290					295						300			
15	Thr	Leu	Ser	Asp	Val	Asp	Asn	Leu	His	Phe	Ile	Leu	Met	Leu	Arg	
		305				310				315					320	
	Gly	Leu	Ser	Gly	Glu	Glu	Gly	Asp	Gln	Ile	Pro	Ile	Leu	Val	Gln	Ile
					325					330					335	
	Ser	His	Gln	Asn	His	Val	Ile	Arg	Glu	Leu	Tyr	Ala	Asn	Ile	Ser	Ala
20					340				345					350		
	Gln	Glu	Gln	Asp	Phe	Ala	Glu	Val	Leu	Pro	Asp	Leu	Ser	Ser	Arg	Glu
			355					360					365			
	Met	Leu	Trp	Leu	Ala	Gln	Gly	Gln	Leu	Glu	Ile	Ser	Val	Gln	Thr	Glu
		370					375					380				
25	Gly	Arg	Arg	Pro	Gln	Ser	Met	Ser	Gly	Ile	Ile	Thr	Val	Arg	Lys	Ser
		385				390					395				400	
	Cys	Asp	Thr	Leu	Gln	Ser	Val	Leu	Ser	Gly	Gly	Asp	Ala	Leu	Asn	Pro
					405					410					415	
	Thr	Lys	Thr	Gly	Ala	Val	Gly	Ser	Ala	Ser	Ile	Thr	Leu	His	Glu	Asn
30					420				425					430		
	Gly	Thr	Leu	Glu	Tyr	Gln	Ile	Gln	Ile	Ala	Gly	Thr	Met	Ser	Thr	Val
					435				440				445			
	Thr	Ala	Val	Thr	Leu	Glu	Thr	Lys	Pro	Arg	Arg	Lys	Thr	Lys	Arg	Asn
		450					455					460				
35	Ile	Leu	His	Asp	Met	Ser	Lys	Asp	Tyr	His	Asp	Gly	Arg	Val	Trp	Gly
		465				470					475				480	
	Tyr	Trp	Ile	Asp	Ala	Asn	Ala	Arg	Asp	Leu	His	Met	Leu	Leu	Gln	Ser
					485					490					495	
	Glu	Leu	Phe	Leu	Asn	Val	Ala	Thr	Lys	Asp	Phe	Gln	Glu	Gly	Glu	Leu
40					500				505					510		
	Arg	Gly	Gln	Ile	Thr	Pro	Leu	Leu	Tyr	Ser	Gly	Leu	Trp	Ala	Arg	Tyr
			515					520					525			
	Glu	Lys	Leu	Pro	Val	Pro	Leu	Ala	Gly	Gln	Phe	Val	Ser	Pro	Pro	Ile
		530						535				540				
45	Arg	Thr	Gly	Ser	Ala	Gly	His	Ala	Trp	Val	Ser	Leu	Asp	Glu	His	Cys
		545				550					555				560	
	His	Leu	His	Tyr	Gln	Ile	Val	Val	Thr	Gly	Leu	Gly	Lys	Ala	Glu	Asp
					565					570					575	
	Ala	Ala	Leu	Asn	Ala	His	Leu	His	Gly	Phe	Ala	Glu	Leu	Gly	Glu	Val
50					580				585					590		
	Gly	Glu	Ser	Ser	Pro	Gly	His	Lys	Arg	Leu	Leu	Lys	Gly	Phe	Tyr	Gly
			595					600					605			
	Ser	Glu	Ala	Gln	Gly	Ser	Val	Lys	Asp	Leu	Asp	Leu	Glu	Leu	Leu	Gly
		610					615					620				
55	His	Leu	Ser	Arg	Gly	Thr	Ala	Phe	Ile	Gln	Val	Ser	Thr	Lys	Leu	Asn
		625				630					635				640	
	Pro	Arg	Gly	Glu	Ile	Arg	Gly	Gln	Ile	His	Ile	Pro	Asn	Ser	Cys	Glu
					645					650					655	
	Ser	Gly	Gly	Val	Ser	Leu	Thr	Pro	Glu	Glu	Pro	Glu	Tyr	Glu	Tyr	Glu
60					660				665					670		
	Ile	Tyr	Glu	Glu	Gly	Arg	Gln	Arg	Asp	Pro	Asp	Asp	Leu	Arg	Lys	Asp
			675					680					685			
	Pro	Arg	Ala	Cys	Ser	Phe	Glu	Gly	Gln	Leu	Arg	Ala	His	Gly	Ser	Arg
		690					695					700				

-11-

	Trp	Ala	Pro	Asp	Tyr	Asp	Arg	Lys	Cys	Ser	Val	Cys	Ser	Cys	Gln	Lys
	705					710					715					720
	Arg	Thr	Val	Ile	Cys	Asp	Pro	Ile	Val	Cys	Pro	Pro	Leu	Asn	Cys	Ser
					725					730						735
5	Gln	Pro	Val	His	Leu	Pro	Asp	Gln	Cys	Cys	Pro	Val	Cys	Glu	Glu	Lys
				740						745						750
	Lys	Glu	Met	Arg	Glu	Val	Lys	Lys	Pro	Glu	Arg	Ala	Arg	Thr	Ser	Glu
			755					760					765			
	Gly	Cys	Phe	Phe	Asp	Gly	Asp	Arg	Ser	Trp	Lys	Ala	Ala	Gly	Thr	Arg
10		770					775					780				
	Trp	His	Pro	Phe	Val	Pro	Pro	Phe	Gly	Leu	Ile	Lys	Cys	Ala	Ile	Cys
	785					790					795					800
	Thr	Cys	Lys	Gly	Ser	Thr	Gly	Glu	Val	His	Cys	Glu	Lys	Val	Thr	Cys
					805					810						815
15	Pro	Lys	Leu	Ser	Cys	Thr	Asn	Pro	Ile	Arg	Ala	Asn	Pro	Ser	Asp	Cys
				820						825						830
	Cys	Lys	Gln	Cys	Pro	Val	Glu	Glu	Arg	Ser	Pro	Met	Glu	Leu	Ala	Asp
			835					840					845			
	Ser	Met	Gln	Ser	Asp	Gly	Ala	Gly	Ser	Cys	Arg	Phe	Gly	Arg	His	Trp
20		850					855					860				
	Tyr	Pro	Asn	His	Glu	Arg	Trp	His	Pro	Thr	Val	Pro	Pro	Phe	Gly	Glu
	865					870					875					880
	Met	Lys	Cys	Val	Thr	Cys	Thr	Cys	Ala	Glu	Gly	Ile	Thr	Gln	Cys	Arg
					885					890						895
25	Arg	Gln	Glu	Cys	Thr	Gly	Thr	Thr	Cys	Gly	Thr	Gly	Ser	Lys	Arg	Asp
				900					905							910
	Arg	Cys	Cys	Thr	Lys	Cys	Lys	Asp	Ala	Asn	Gln	Asp	Glu	Asp	Glu	Lys
			915					920					925			
30	Val	Lys	Ser	Asp	Glu	Thr	Arg	Thr	Pro	Trp	Ser	Phe				
	930						935					940				

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/20675

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07K 14/435; C12N 1/13, 5/10, 15/12, 15/63; A61K 38/17

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 69.1, 320.1, 325, 252.3; 436/86; 514/12; 530/350, 388.15; 536/23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, BIOSIS, MEDLINE, EMBASE

search terms: huchordin, chordin

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,E	US 5,846,770 A (LA VALLIE et al) 08 December 1998, entire document, especially sequence listing.	1-39
A,P	US 5,679,783 A (DE ROBERTIS et al) 21 October 1997, entire document, especially sequence listings.	1-39



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 DECEMBER 1998

Date of mailing of the international search report

25 JAN 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DIAN JACOBSON

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/20675

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/6, 69.1, 320.1, 325, 252.3; 436/86; 514/12; 530/350, 388.15; 536/23.5